Structural biology of Schistosome: Glutathione Peroxidase and Thioredoxin Glutathione Reductase from a human parasite by Dimastrogiovanni, Daniela
  
 
 
“Structural biology of Schistosome: 
Glutathione Peroxidase and Thioredoxin Glutathione Reductase 
from a human parasite” 
 
 
 
      Docente guida                                        Coordinatore 
 
             Prof. Maurizio Brunori            Prof. Marco Tripodi 
 
 
Dottoranda 
 
Daniela Dimastrogiovanni 
 
XXIII CICLO 
  
ACKNOWLEDGEMENTS 
 
Firstly I would like to thank Prof. Maurizio Brunori who allowed me to join his 
group in Rome during my PhD and Prof. Andrea Bellelli, for his guidance and 
support all along the development of this project. 
I would like also to thank my colleagues Dr. Francesco Angelucci, Dr. Giovanna 
Boumis, Prof. Adriana Miele, Dr. Fulvio Saccoccia, who shared with me the daily 
wet lab work and for all the scientific and lunch-time discussions. 
Many thanks to Nicoletta, Francesca, Enrico, Giorgio, Stefano, Lindina, Ilias, and all 
the people from the Department of Biochemical Sciences, whose friendship and 
hilarity have enriched and made more funny my time in Rome. 
I would like also to thank Prof. Ben Luisi for having hosted me in his lab in 
Cambridge for the last months of my PhD, allowing me to face new and interesting 
scientific problems. 
A final great thank to my family for their constant support and in particular to 
Tommaso, who made more special everyday of this adventure. 
Contents 
 
 
CONTENTS 
 
CHAPTER  
1. INTRODUCTION................................................................................................. 1 
1.1 Schistosomiasis: a water-born disease............................................................... 1 
1.2 Infection and progression of the disease ........................................................... 3 
1.2.1 The parasite .................................................................................................... 3 
1.2.2 Immunopathogenesis...................................................................................... 5 
1.2.3 Clinical features ............................................................................................. 7 
1.3 Prevention and morbidity control ..................................................................... 8 
1.3.1 Prevention strategies ...................................................................................... 8 
1.3.2 Chemotherapeutic approaches and current therapy ..................................... 10 
1.4 Main tracks of current bio-medical research ................................................. 12 
1.4.1 Discover new drug combinations................................................................. 12 
1.4.2 Identify drug targets and vaccine candidates ............................................... 14 
1.4.3 The Schistosoma thiol-detoxification pathway: a promising target............. 15 
1.5 The Schistosoma Glutathione Peroxidase (Gpx) ............................................ 21 
1.5.1 The Gpx family: an overview ...................................................................... 21 
1.5.2 The parasite Gpx and its interest for antischistosomal therapy.................... 23 
1.6 The Schistosoma Thioredoxin Glutathione Reductase (TGR)...................... 24 
1.6.1 Different roles of mammalian and parasite TGRs ....................................... 24 
1.6.2 Inhibitors of SmTGR as antischistosomal drugs.......................................... 25 
3. MATERIALS AND METHODS ....................................................................... 31 
I part: Glutathione peroxidase from S. mansoni (SmGpx) ................................. 31 
3.1 Mutagenesis ....................................................................................................... 31 
3.2 Protein expression ............................................................................................. 31 
3.3 Protein purification ........................................................................................... 31 
3.4 Size exclusion chromatography .......................................................................... 32 
3.5 Enzymatic assays ............................................................................................... 32 
3.6 Protein crystallization ....................................................................................... 33 
Contents 
 
3.6.1 Basic procedure ............................................................................................33 
3.6.2 Crystallization of U43C and U43S SmGpx..................................................35 
3.7 Data collection, processing and refinement.....................................................35 
3.8 Sequence alignment ...........................................................................................36 
3.9 Surface analysis..................................................................................................36 
3.11 Docking .............................................................................................................36 
3.10 Molecular Dynamic (MD) simulations...........................................................36 
II part: Thioredoxin Glutathione Reductase from S. mansoni (SmTGR)..........38 
3.12 Mutagenesis ......................................................................................................38 
3.13 Protein expression and purification ...............................................................38 
3.14 Protein crystallization .....................................................................................39 
3.14.1 Truncated SmTGR......................................................................................39 
3.14.2 Oxidized U597C SmTGR (Structure 1) .....................................................39 
3.14.3 U597C SmTGR-NADPH complex (Structure 2) .......................................39 
3.14.4 U597C SmTGR with reduced C-terminal end (Structure 3) ......................40 
3.14.4 U597C SmTGR-GSH complex (Structure 4) .............................................40 
3.15 Data Collection, Processing and Refinement ................................................40 
3.15.1 Structure 1, Structure 2 and Structure 4......................................................40 
3.15.2 Structure 3...................................................................................................41 
3.16 Modeling ...........................................................................................................41 
3.16.1 Model 1: the C-terminus of U597C SmTGR onto the Grx domain ...........41 
3.16.2 Model 2: the SmTGR-SmTrx complex ......................................................42 
3.17 Kinetic measurements .....................................................................................42 
3.17.1 TR activity ..................................................................................................42 
3.17.2 GR activity..................................................................................................43 
3.17.3 Grx activity .................................................................................................43 
3.17.2 Reductive half-reaction of U597C SmTGR ...............................................43 
3.17.3 Oxidative half-reaction of U597C SmTGR................................................44 
4. RESULTS AND DISCUSSION ..........................................................................45 
I part: Glutathione peroxidase from S. mansoni (SmGpx)..................................45 
Contents 
 
 
4.1 Expression and purification of two mutants of SmGpx ................................ 45 
4.2 Structural characterization of U43C and U43S SmGpx ............................... 47 
4.2.1 Analysis of the primary structure of SmGpx ............................................... 47 
4.2.2 Overall 3D structure of U43C and U43S SmGpx mutants .......................... 48 
4.2.3 Insight into the catalytic site of SmGpx....................................................... 52 
4.2.4 Static and dynamic clefts on SmGpx and their functional relevance........... 55 
II part: Thioredoxin Glutathione Reductase from S. mansoni (SmTGR) ......... 62 
4.3 Expression and purification of two mutants of SmTGR ............................... 62 
4.4 Structural characterization of intermediates of the catalytic cycle of 
SmTGR..................................................................................................................... 63 
4.4.1 The oxidized form of SmTGR (Structure 1)................................................ 67 
4.4.2 The complex SmTGR-NADPH (Structure 2).............................................. 76 
4.4.3 The C-terminal reduced form of SmTGR (Structure 3)............................... 79 
4.4.4 The complex SmTGR-GSH (Structure 4).................................................... 80 
4.5 Functional studies on SmTGR ......................................................................... 82 
4.5.1 Enzymatic activities of U597C SmTGR...................................................... 82 
4.5.2 Reductive and oxidative half reactions of U597C SmTGR......................... 85 
4.6 Modeling of the complexes mediating the electron-transfer from SmTGR to 
both Grx domain and SmTrx ................................................................................. 88 
4.6.1 Model 1. The C-terminus of SmTGR onto the Grx domain ........................ 89 
4.6.2 Model 2. The complex between SmTGR and SmTrx.................................. 91 
4.7 The catalytic mechanism of SmTGR ............................................................... 91 
4.7.1 Electron flow within the TR domain: from NADPH to the C-terminus ...... 92 
4.7.2 Electrons exit from the TR domain: from the C-terminus to either SmTrx or 
the Grx domain...................................................................................................... 93 
5. CONCLUDING REMARKS.............................................................................. 95 
6. BIBLIOGRAPHY..............................................................................................101 
7. PUBLICATIONS……………………………………………………………...111 
 
Chapter 1 
 
1 
1. INTRODUCTION 
 
1.1 Schistosomiasis: a water-born disease 
Schistosomiasis, also known as “Bilharziasis” from the name of the German 
pharmacist Theodor Bilharz who described the illness in 1851, is a human parasitic 
disease still affecting more than 200 million people especially in tropical and 
subtropical countries [1]. The control programmes adopted in the last twenty years 
have changed to some extent the worldwide distribution of the disease, but 
Schistosomiasis still remains a real scourge in more than 74 endemic countries (Fig. 
1, [2]). Asia, South-America and sub-saharian Africa count about 200,000 deaths per 
year, 85% of them belonging to the African continent [2, 3].  
 
 
 
 
 Fig. 1: Geographical distribution of Schistosomiasis (adapted from [2]).  
 
A flatworm parasite of the genus Schistosoma (see section 1.2.1) is the 
causing agent of the disease (Fig. 2). The worm spends part of his life cycle in the 
freshwaters using a snail as intermediate host before being ready to infect humans. 
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Thus it is not surprising that the earliest infection from the parasite was detected in 
1914 in Egypt in people working for the construction of the first great dam across 
the Blue Nile river. The project, the so-called “Gezira Scheme”, was a real 
commercial success but the rapid growth of artificial water canals created soon an 
ideal habitat for the snails and provided the basis for the diffusion of 
Schistosomiasis. The infected people were treated with tartar-emetic but the spread 
of the disease was unavoidable. During the 20th century lots of projects resembling 
the “Gezira Scheme” caused the dramatic spread of the disease in the developing 
countries [4].  
 
 
 
 
 Fig. 2: A couple of paired worms (Schistosoma mansoni). The male is holding the female in the 
gynecophoral canal, a longitudinal groove down his body. 
 
 
Nowadays Schistosomiasis is second only to malaria for prevalence and 
number of deaths. The reasons for the difficulty of eradication of Schistosomiasis 
are various but we can say that, besides the difficulties in finding an effective 
pharmacological solution and the extremely easy transmission of the parasite in 
endemic areas, poverty itself is certainly both a cause and a consequence of the 
disease spreading. The access to clean water is still rare in the poorest countries, this 
increases the probability for local people to be affected by Schistosomiasis and other 
water-born diseases. Moreover, being these infections often chronic and really 
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disabilitating, they augment undernutrition and reduce people productivity, with the 
final result of ever-increasing poverty [5]. 
 
1.2 Infection and progression of the disease 
1.2.1 The parasite 
As mentioned above human Schistosomiasis results from the infection by a 
bloodfluke worm, a platyhelminth of the genus Schistosoma. The adult parasites are 
white, approximately 1 cm long and 0.11 cm wide and, differently from the other 
trematode species, schistosomes have separate sexes. Females have a cylindrical 
body, they are longer and thinner than males and can be hosted in a groove, the 
gynaecophoric channel, present in the body of the male worm. Once paired the two 
partners live permanently coupled within the venous system of the human host, 
feeding themselves with erythrocytes. The localization of the adult schistosomes 
inside the human body depends on the infecting species. Schistosoma mansoni and 
S. japonicum, cause hepato-intestinal Schistosomiasis as they migrate into the 
mesenteric circulation once matured to the adult stage, while S.  haematobium is 
responsible for the genito-urinary form of the disease, being localized in the venous 
system which surrounds the human bladder. Minor species with limited geographical 
distribution are S. intercalatum and S. mekongi (Fig. 3). 
The parasites can remain in the human host for a period that varies from three 
to thirty years, and in the meantime the adult females are able to produce 100-300 
eggs per day. Some of the eggs are able to reach the lumen of the intestine (S. 
mansoni and S. japonicum) or of the bladder (S. haematobium) and are then excreted 
through feces or urines (Fig. 4). Once in contact with the freshwater the eggs hatch 
releasing miracidia, which represent the first larval stage of the parasite. Each 
miracidium searches for its intermediate host, a snail of the genus Biomphalaria (for 
S. mansoni), Bulinus (for S.  haematobium) or Oncomelania (for S. japonicum), and 
penetrates it. The snail is required by the parasite to proceed through a series of 
asexual reproductions. A single snail can release in the freshwater thousands of 
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swimming larvae, the cercariae, which finally recognize and penetrate the human 
skin using their bifurcated tails. 
 
 
 
 
Fig. 3: The life cycle of the three most infective species of schistosoma (S. mansoni, S. haematobium and S. 
japonicum) [1]. 
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Fig. 4: S. mansoni egg. The schistosome eggs have terminal or lateral spines trough which they can penetrate the 
host tissues. 
 
The head of the cercaria transforms into an endoparasitic larva, the 
schistosomula, which lives for a few days under the skin before being ready to enter 
the lymphatic and venous circulation. The larvae migrate to the lungs and from here 
to the heart reaching finally the hepatoportal circulation, where schistosomulae 
develop into sexually mature worms within 4-6 weeks. Schistosome couples reach 
their definitive district in the human body according to the parasite species, females 
begin to produce eggs and the parasite life cycle starts again (Fig. 4).  
 
1.2.2 Immunopathogenesis 
A number of eggs produced during the schistosome permanence inside his 
definitive host are not released outside the human body, but are permanently 
entrapped in the host tissues. Thus it is not surprising that the main symptoms of 
chronic schistosomiasis develop at the sites of major accumulation of eggs, i.e. the 
intestine and the liver (S. mansoni and S. japonicum) or the genitourinary apparatus 
(S. haematobium). Many studies have been carried out in animal models of 
Schistosomiasis in order to clarify the involvement of the immunitary system in the 
pathogenesis of the disease. Independently from the parasite species and from the 
infected organism, it is now clear that the eggs’ antigens induce a strong CD4+ T-
cell mediated response that directs a granulomatous reaction. The formation of 
granulomas proceeds from the early accumulation of macrophages, which take up 
the secreted eggs’ antigens. These mononuclear cells both present the antigens on 
Introduction 
 
6 
their surface and secrete limphokines that attract different immune cells around the 
deposited egg: especially CD4+ T-cells, B-cells, neutrophils and eosinophils. In the 
latest stages of the granuloma formation epitheloid cells and fibrocytes accumulate 
at the periphery of the lesion, finally becoming predominant over the other cell 
types. As the granuloma matures the egg is disintegrated and become calcified, 
while the fibrocytes mediate the massive deposition of collagen, which finally leads 
to fibrosis and to a progressive decay of functionality of the organs interested by the 
granulomatous reactions (Fig. 5). 
 
 A B  
 
 
 
 
 
Fig. 5 Panel A: granuloma in the liver due to Schistosoma mansoni, the S. mansoni egg is at the center of the 
granuloma. Panel B: representation of an hepatic granuloma showing its cellular composition (adapted from 
[6]). 
 
It is clear that the severity of the disease correlates better with the 
alteration/modulation of the host immune response, rather than with the parasite 
burden inside the host. Results obtained from the study of the murine form of the 
disease have demonstrated that a T helper-1 (Th1) mediated immune response 
dominates the earlier stages of the disease. When the parasite is sexually mature and 
starts to produce eggs the T helper-2 (Th2) response becomes dominant on the 
former. The Th2 prolonged action seems to be directly involved in the granuloma 
formation. Some cytokines released during this secondary response, among them IL-
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4 and IL-13, have been demonstrated to have a fibrogenic role, as mice deprived of 
IL-13 do not develop fibrosis as a consequence of Schistosoma infection. These 
molecules should induce the expression of the enzyme arginase inside macrophage 
and should activate the biosynthetic pathway that leads to the synthesis of the 
aminoacid proline, an essential precursor for the production of collagen [6, 7]. 
Unfortunately the specific pattern of immune cells and chemical signals that are 
activated as a consequence of the Schistosoma infection in humans is not completely 
elucidated yet. However the progression of the infection is accompanied also in 
humans by a change from Th1 to Th2 mediated immune response, and IL-13 seems 
to be the main fibrogenic cytokine in humans too, while IL-4, IL-10 and INF-γ could 
play an important role in controlling morbidity [6, 8]. 
 
1.2.3 Clinical features 
The clinical symptoms of Schistosomiasis are different depending either on 
the number of exposures of the patient to the parasite or on the particular infecting 
species. A distinction between acute and chronic disease may be easily drawn. 
Usually travellers, who are subjected to a single contact with the worm, present the 
typical manifestations of acute Schistosomiasis: cercarial dermatitis and katayama 
fever. The former is characterized by a pruritic rash which results from the IgE-
mediated immune response to the cercaria penetration; the latter manifests 14-84 
days after the infection and determines fever, headache, myalgia, cough, general 
malaise, sometimes accompanied by abdominal pain as a result of the migration of 
juvenile worms through the human body [6]. The chronic form of Schistosomiasis, 
involving mainly the endemic populations, is more dependent on the infecting 
species which localize, as above mentioned, in typical anatomic districts of the 
mammalian host. Abdominal pain, loss of appetite and rapid weight loss, diarrhoea, 
vomit, together with portal hypertension, splenomegaly, ascites, gastrointestinal 
bleeding and periportal fibrosis in the late stages are usually associated with the 
development of granulomatous lesions consequently to S. mansoni and S. japonicum 
migration to the hepatic and intestinal districts. Anaemia may accompany these 
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symptoms causing wasting in adults and growth retardation in children. The 
infection with S. haematobium instead involves the genitourinary apparatus and has 
as major symptoms renal colics, fibrosis and calcification of the bladder and ureters 
where the parasite eggs are accumulated, leading to a gradual renal failure. A series 
of co-infections sometimes may complicate the clinical prospect of patients affected 
by Schistosomiasis. It has been pointed out that hepatitis C (HCV) and B (HBV) 
viruses have a crucial role in increasing morbidity due to S. mansoni infection, as 
they accelerate progression of the disease towards liver fibrosis and cirrhosis. On the 
other hand it is not so uncommon that women affected by genitourinary 
Schistosomiasis are subjected to infertility if the parasite reaches the uterus, tubes or 
ovaries, and usually they have a higher tendency to the transmission of sexually 
transmitted infections such as HIV, because of the development of ulcerative lesions 
in the genital tract as a consequence of the egg deposition in this district. In addition 
to the above-described variants of Schistosomiasis, the lung district and the CNS 
may be also damaged by the parasite infection although with fewer incidence. 
Neuroschistosomiasis, mainly caused by S. mansoni, has not been extensively 
studied yet but preliminary evidences suggest a pathogenesis similar to the hepatic-
intestinal and genitourinary form of the disease. Eggs trapped in the CNS tissues 
should evoke an immune response probably Th2-mediated, with the consequent 
development of granulomatous lesions and serious damaging of the host nervous 
tissues [6, 9]. 
 
1.3 Prevention and morbidity control 
1.3.1 Prevention strategies 
Schistosomiasis morbidity and mortality have been underestimated for years 
and the spreading of the disease has made urgent the finding out of effective and 
preventive control measures. 
The water-based diffusion of Schistosomiasis suggested that a regular 
provision and use of safe water and an appropriate health education, together with 
specific environmental management programs aimed at reducing the contamination 
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of water resources, might represent a good strategy to promote hygiene and 
sanitation and eventually to reduce the morbidity in some areas. Even if these 
initiatives have had only limited success till now, it is indeed general opinion that, 
given the high rate of reinfection in endemic areas such interventions, aimed to 
break the parasite transmission routes, could be extremely useful though far from 
representing the final solution for Schistosomiasis [5, 10].  
A vaccine applicable to humans could represent a key step towards the 
definitive eradication of the disease, but a vaccine production has proved to be rather 
tricky. The main reason for that can be found in the ability of schistosomes to 
survive for decades in the human bloodstream, evading the host immune defenses 
through different highly effective mechanisms: (i) they mask themselves through the 
absorption of some host serum proteins; (ii) they evade the immune attack by 
producing antigens with epitopes similar to those of the host; (iii) they modulate the 
human immune response in order to reduce the parasite-specific immunity and 
assure their life-maintenance into the host [11, 12]. 
In spite of the ability of the parasite to elude the human defenses, some 
experimental evidences demonstrate that the development of a successful vaccine is 
a realistic prospective: (i) the immunization of mice with irradiated cercariae 
conferred them 50-70% protection, and (ii) the repetitive exposition of people living 
in endemic areas to schistosome infection finally results in the natural development 
of a partial protection [13]. Based on these premises in the last decade various 
molecular candidates for the design of a vaccine against Schistosomiasis have been 
proposed; glutathione-S-transferase [14], paramyosin [15], triose phosphate 
isomerase [16], fatty acid binding protein (FABP, [17]), Sm23 ([18]), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, [19]) are among them. 
Recent evidences suggest also that DNA-mediated vaccination with antioxidant 
enzyme, such as superoxide dismutase (SOD) confers a certain degree of protection 
against schistosome infection [20, 21]. According to the WHO directions, which 
established that an effective vaccine should induce at least 40% protection in mice 
infected, some of the discovered antigens, SOD among them, are ready to enter the 
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human clinical trial phase. However most of the current schistosome vaccine 
candidates do not confer more than 50% protection in animal models, thus further 
efforts are needed either to develop adjuvant molecules, which can enhance 
protection levels, or to find out new more effective parasite antigens [13]. 
  
1.3.2 Chemotherapeutic approaches and current therapy 
Because of the unavailability of an effective human vaccine a huge amount of 
schistosomicidal compounds have been employed in the last century to counteract 
the spread of the disease [22]. The main compounds proposed as drugs against 
Schistosomiasis are listed in Fig. 6. 
In the early 1900s the first schistosome contagions were treated with an 
antymonial salt, namely tartar emetic (or potassium antymonium tartrate). The drug 
unfortunately proved to be toxic, as the excretion of the metal from human tissues 
could take several weeks and in the meantime a number of serious side effects 
appeared. Several years later, oltipraz and artemether were proposed as valid 
chemotherapeutic alternatives. Oltipraz, a dithiole thione derivative, is no longer 
employed in the clinic of schistosome infections because of its serious dose-related 
side effects, such as paresthesiasis and loosening or detachment of fingernails [23].  
Still rather promising antischistosomal drugs seem to be represented by 
metrifonate, oxamniquine and artemether. Metrifonate, an organophosphorous 
compound, was demonstrated to be an acetylcholinesterase inhibitor, with a strong 
activity against S. haematobium species. Today it is still one of the WHO 
recommended drugs for the treatment of urinary Schistosomiasis [22]. On the other 
hand the therapy of S. mansoni infections has been based for many years on the 
employment of oxamniquine, a tetrahydroquinoline derivative, which is easily 
administered orally to patients and has no relevant side effect. Much is known about 
its mechanism of action: the drug is activated by a schistosome sulphotransferase 
enzyme, the active metabolite is able to alkylate DNA, causing cellular damage and 
finally leading to the death of the worm [23, 24]. Artemether, an artemisinin 
derivative, is a very well tolerated compound, demonstrated to be active against the 
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juvenile stages of all three main species of schistosome infecting humans [25]. 
Artemisinins are at the moment widely used in the treatment of malaria, thus their 
employment as antischistosomal agents is forbidden especially in areas where the 
two parasitic diseases are co-endemic, in order to avoid the development of 
Plasmodium strains resistant to the drug. 
Unfortunately the species- and stage-specificity of these drugs have limited till 
now their employment in the large scale treatment of Schistosomiasis, thus the 
current chemotherapy is mostly based on praziquantel, a drug discovered in the 
mid-1970s and administered to several millions people for more than 20 years (Fig. 
6). Praziquantel is a pyrazino-isoquinoline derivative, commercially available as a 
very low cost drug, easily administered through a single oral dose. It is effective 
against all species of schistosomes infecting humans, though the juvenile stages are 
less susceptible then the adults to the drug, and lacks both short-term and long-term 
relevant side effects [23]. At the moment the drug is commercially available as a 
racemic mixture of L- and D-praziquantel, but only the L-optical isomer is active, 
and its mechanism of action is actually still puzzling. It is known that the 
administration of praziquantel causes the disruption of the worm tegument and 
enhances the muscular contraction, but it is neither clear if this last effect is 
mediated by an increase of the intracellular concentration of Ca2+, involving the 
action of the drug on the parasite voltage-gated Ca2+ channels, nor if praziquantel 
induced tegumental damaging may lead to the exposure of the schistosome antigens, 
which finally elicit the host's immune responses against the parasite [22]. Recently a 
new study suggested that the drug might act as an inhibitor of nucleoside uptake by 
the parasite, a relevant effect since the schistosome is unable to synthesize purine 
nucleosides de novo [26]. Besides its uncertain molecular target praziquantel has 
been administered to several millions people, giving a large contribution to reduce 
the worm burden in endemic areas and to limit the disease spreading. However it 
must be pointed out that the massive use of this unique drug is resulting in the 
emergence of schistosome strains resistant or less susceptible to the drug [27], which 
makes urgent the search for valid therapeutic alternatives.  
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1.4 Main tracks of current bio-medical research 
1.4.1 Discover new drug combinations  
The use of a single drug in the treatment of Schistosomiasis, with the actual 
resulting problem of resistance, puts the current chemotherapy under danger and 
shows how pressing the need for more effective drugs is. In the last years interesting 
chemical compounds have emerged for their schistosomicidial effect (Fig. 6). In 
particular a high-throughput screening identified oxadiazole 2-oxides and 
phosphinic amides as the more effective compounds, for their ability to inhibit the 
activity of thioredoxin glutathione reductase (TGR), an enzyme essential for the 
parasite survival into the human host. The toxicity of these proposed 
antischistosomal drugs is not very different from that of praziquantel, and some of 
these compounds, furoxan among them, are able to reduce the worm burden in mice 
infected with the parasite by more than 80% [28]. Such values exceed the WHO 
criteria for the selection of drugs to employ in the treatment of the disease, thus the 
research work is still in progress to generate effective derivative compounds to be 
used in the clinic of human Schistosomiasis. 
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Auranofin 
 
 
 
Furoxan (4-phenil-3-furoxan carbonitrile) 
                    
 
 
Fig. 6: List of the main chemotherapeutic compounds employed in the treatment of human Schistosomiasis 
since the early 1900s and recently proposed schistosomicidial compounds. 
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An alternative approach to the finding out of new chemotherapeutic candidates 
relies in the attempt to employ old drugs already in clinical use for other human 
diseases. This is the case of auranofin ([AuI(PEt3)(thioglucose)]), a gold-containing 
compound used to cure rheumatoid arthritis for 25 years, and which has been 
recently demonstrated to be highly effective as schistosomicidial drug [29] (Fig. 6). 
Finding new uses of clinically established drugs, which have a well-known and quite 
safe toxicity profile, represents a clever strategy of drug discovery considering the 
drastic reduction in times and costs [30]. These considerations become of extreme 
importance especially when we are dealing with research on neglected diseases such 
as Schistosomiasis that have a limited financial market, being not attractive for the 
funding providing organizations.  
 
1.4.2 Identify drug targets and vaccine candidates 
In the last decade a series of schistosome proteins has been selected for their 
potential interest in the treatment of Schistosomiasis. Some of them, suggested 
either as potentially “druggable” proteins or as vaccine candidates, are grouped 
below: 
• Enzymes required in the different stages of schistosome infection: (i) 
proteolytic enzymes, involved both in the early stages of cercarial penetration 
[31] and in the adult life of the parasites when, especially cysteine proteases, 
seem to be involved in the suppression of the human Th1-mediated response in 
order to assure the parasite survival into its host [32]; (ii) phenol oxidases 
(tyrosinase 1 and 2), copper-containing glycoenzymes, which play a key role 
in the eggshell formation and production [33]. Their inhibition is likely to be 
crucial for the prevention of the egg-induced inflammatory reactions, which 
open the road to the development of the chronic disease symptoms.   
• Factors crucial for the parasite life-maintenance: (i) protein kinases, which 
are involved in intracellular signaling pathways in adult worms. One of them, 
cAMP-dependent protein kinase A (PKA) has recently proved to be essential 
for the parasite viability in vitro [34]; (ii) cyclophillins, enzymes with a 
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peptidyl prolyl isomerase activity, involved in protein folding and chaperoning 
mechanisms. Their interest as potential drug target has increased when recently 
a cyclophillin from S. mansoni has been demonstrated to be efficiently 
inhibited by cyclosporine [35], a compound with a proved antiparasitic effect 
[36]; (iii) voltage-gated calcium channels [37], whose modulation may 
determine an increase of the calcium influx into the worm with the resulting 
muscle contraction and paralysis, one of the proposed and discussed effects of 
praziquantel; (iv) enzymes required for the parasite redox homeostasis 
(discussed in detail in section 1.4.3). 
• Proteins localized at the host-parasite interface: lots of surface-exposed 
tegumental proteins have been recently identified, among them transport 
proteins, heat shock proteins and tetraspanins. It is clear that, being the worm 
tegument directly involved in the mechanisms of evasion of the host immune 
response, its protein components could be extremely useful in the future design 
of a human vaccine [38].  
 
1.4.3 The Schistosoma thiol-detoxification pathway: a promising target 
Adult Schistosomes spend their entire life in the bloodstream of the human 
host, where they are constantly subjected to oxidative stress determined by the 
reactive oxygen species (ROS) that come both from their own aerobic metabolism 
and from the immune response of the host phagocytes to the parasite infection. 
Macrophages as well as neutrophil, eosinophil or basophil granulocytes, in fact, 
contain several enzymes which produce free radicals in order to fight the infectious 
agent [39, 40]. All aerobic organisms require protection against ROS; reactive 
species such as superoxide anion radicals (O2-˙), hydrogen peroxide (H2O2), and 
hydroxide radicals (OH˙), are able indeed to trigger radical reactions which may 
result in severe cellular damage through the oxidation of protein, lipids and nucleic 
acids.  
Mammals possess two main systems devoted to the detoxification of these 
highly damaging compounds: the thioredoxin (Trx) and the glutathione (GSH) 
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systems (Fig. 7) [42]. Two redox cascades are headed by Thioredoxin Reductase 
(TR) and Glutathione Reductase (GR) enzymes respectively. TR and GR are 
homodimeric flavoenzymes, belonging to the family of pyridine nucleotide disulfide 
oxidoreductases, involved in various cellular processes crucial for cell function and 
proliferation, besides their key role in redox homeostasis and antioxidant defense 
[43]. Crystallographic evidences proved the high structural similarity between TR 
and GR. The two proteins share the main structural fold and the arrangement of the 
binding sites for NADPH and FAD. Indeed the main difference between TR and GR 
resides in the C-terminal segment of the polypeptidic chains, where the former 
protein presents a selenocysteine (Sec) residue located in a Gly-Cys-Sec-Gly 
tetrapeptide, essential for the full catalytic activity and absent in GR (Fig. 8) [43, 
44]. Both enzymes are able to shuttle reducing equivalents from NADPH to 
peroxidated substrates, by means of a series of thiol-/selenol-mediated redox 
exchange reactions involving intermediate enzymatic and non-enzymatic partners 
(Fig. 7). Trx peroxidases (Tpx) in addition to Trxs are the other components of the 
Trx system, while the GSH system involves GSH Peroxidase (Gpx) and 
Glutaredoxin (Grx), an oxidoreductase acting on S-glutathionylated substrates [45, 
46]. 
All species of Schistosoma (e.g. japonicum, mansoni, haematobium) have 
evolved an enzymatic mechanism quite different from their mammalian host in order 
to protect themselves by oxidative damage. It is based on a single multifunctional 
oxidoreductase, namely Thioredoxin Glutathione Reductase (TGR), which transfers 
reducing equivalents to both GSH and Trx systems (Fig. 7) [39]. A recent analysis 
of the platyhelminth genomes and transcriptomes has found out that, while free 
living Plathyhelminths (class Turbellaria) possess the three types of antioxidant 
enzymes (TR, GR and TGR), platyhelminth parasites (Schistosoma, E. granulosus, 
T. solium, F. hepatica) have lost the genes coding for TR and GR as a result of their 
adaptation to the endoparasitic life, and depend on the single TGR enzyme to control 
redox homeostasis [47]. The peculiarity of the parasite detoxification system, relying 
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on the unique TGR enzyme, explains why this pathway currently provides excellent 
enzymatic targets in the search for new antischistosomal drugs. 
The main components of Schistosoma linked thioredoxin-glutathione 
detoxification system are represented in Fig. 7, though the correct positioning and 
relations betweens some of them inside the pathway have not been fully clarified 
yet. TGR is the hub enzyme, able to exploit the three enzymatic activities of 
thioredoxin reductase, glutathione reductase and glutaredoxin, through the unique 
fusion of a TR with a glutaredoxin (Grx) domain. It is because of its peculiarity that 
TGR has been recently proposed and partially validated as one of the most 
promising drug targets against Schistosomiasis [29, 48]. A more detailed description 
of Schistosoma TGR and a review of the recent concerning literature will be 
provided in section 1.6. 
The intermediate thiol-exchange reactions, that precede the reduction and 
detoxification of peroxides, involve Trx and GSH as direct substrates of TGR. 
Schistosoma thioredoxin is a 12 KDa monomeric protein, containing a redox-active 
site with the conservative motif CXXC [49]. When this cysteine couple is recycled 
to its reduced state by TGR, Trx is able to provide reducing equivalents to its 
substrates, such as ribonucleotide reductase and thioredoxin peroxidase (TPx). On 
the other hand TGR can supply electrons to the oxidized tripeptide γ-L-Glutamyl-L-
cysteinylglycine (GSSG), which once reduced may act as the substrate of other 
enzymes, e.g. Glutathione Peroxidase (Gpx), though it is still controversial if Gpx is 
maintained in its reduced state by GSH or by an enzymatic partner. The parasite Gpx 
is classified as a phospholipid hydroperoxide glutathione peroxidase enzyme, being 
able to reduce peroxides of phospholipids and cholesterol more efficiently than H2O2 
and other organic peroxides [50, 51]. Its direct role in the protection of the parasite 
membranes from oxidation and its localization on the tegument of the worm make 
Gpx a potential target either for the development of drugs or for the design of 
vaccine against Schistosomiasis [20]. Further details about the parasite Gpx will be 
provided in section 1.5. 
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The detoxification pathway of the worm comprises also the parasite 
Peroxiredoxins (Prx), which have been recently proved to be the major family of 
antioxidant enzymes involved in the detoxification of H2O2 in Schistosomes. This 
result is compatible with the observation that parasites lack catalase, which usually 
works as H2O2-scavenger, and express high levels of superoxide dismutase (SOD), 
whose O2-˙-detoxifying activity results in the release of hydrogen peroxide. Taking 
into account the fact that the parasite Gpx has a poor reactivity towards H2O2 if 
compared with lipid peroxides, it is clear that the role of Prx is crucial for the 
parasite survival. It has been demonstrated in S. mansoni the existence of at least 
three Prx enzymes, belonging to the class of 2-Cys Prxs: Prx1, Prx2, Prx3. The three 
proteins are highly effective in the reduction of H2O2 using reducing equivalents 
provided by Trx, but Prx2 and Prx3 seem to be more efficient in accepting electrons 
from the GSH system [52]. In vitro experiments of RNA interference, performed 
incubating schistosomulae with Prx1 double-stranded RNA, have proved that also 
this enzyme is essential for the parasite survival and can be thus classified among 
the promising target of antischistosomal therapy [53]. 
 
A 
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Fig. 7: Antioxidant detoxification pathways in mammals and platyhelminths (adapted from [41]). The 
electron flow in the Trx and GSH systems of mammals and TGR system of platyhelminths is shown. 
Panel A: In mammals, NADPH donates electrons to both TrxR and GR; TrxR shuttles electrons to Trx, 
which directly reduces TPX and various oxidized targets, such as ribonucleotide reductase. GR converts 
oxidized glutathione (GSSG) to its reduced form (GSH). GSH donates electrons to Gpx, Grx and other 
oxidized targets. Gpx and Grx are able to reduce peroxides and GSH-mixed disulphides respectively. 
Panel B: Platyhelminths have a single hub enzyme, TGR, which exploits the functions of either 
mammalian GR, TrxR and Grx. In both pathways the Grx redox site is shown in green, the FAD redox 
site in yellow, and the C-terminal tetrapeptide GCUG in violet. 
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Fig. 8: Primary structure of TGR, TR, GR, GRX and TRX enzymes. The NADPH and FAD binding 
domains on TGR, TR, and GR is shown, with the close cysteine couple contained in a CXXXXC motif. 
The C-terminal GCUG tetrapeptide is present in TR and TGR but absent in GR. The CXXC motif 
containing the catalytic cysteine couple on the Grx domain of TGR is shown [39].  
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1.5 The Schistosoma Glutathione Peroxidase (Gpx) 
1.5.1 The Gpx family: an overview 
Glutathione peroxidase (Gpx) is the general name given to a family of 
antioxidant enzymes that catalyze the reduction of hydrogen peroxide and organic 
hydroperoxides to water or the corresponding alcohols, usually using reduced 
glutathione (GSH) as electron donor, according to the following reaction: 
ROOH + 2GSH → ROH + H2O + GSSG 
where ROOH is an organic or inorganic peroxide (including H2O2). 
The variety of existing Gpx isozymes, showing various molecular 
organizations, cellular localizations and substrate specificities, reflected so far in the 
difficult efforts to give a definitive classification to the Gpx family [54]. In spite of 
this complexity, at the moment it is possible to identify at least six classes of 
enzymes: cytosolic or classical (Gpx1); gastrointestinal (Gpx2); plasma secreted 
Gpx (Gpx3); Gpxs with specificity for phospholipid hydroperoxides substrates 
(PhGpx or Gpx4); Gpxs localized in the epididymal (Gpx5) and olfactory epithelium 
(Gpx6) [54-56]. Recently a philogenetic analysis has proved Gpx4 to be the ancestor 
among Gpx isozymes. It seems likely that, by a first duplication event, the ancestral 
gene of Gpx4 lead to the formation of two groups of genes: the first coding for 
intracellular Gpx1 and Gpx2 isozymes, and the second coding for the secreted Gpx3, 
Gpx5 and Gpx6 [55].    
All Gpx isozymes except Gpx5 and Gpx6 are selenium-containing proteins, 
having a selenocysteine residue (Sec) in their active site. The Sec residue, referred to 
as the 21st amino acid, is encoded by a UGA codon, which is otherwise usually 
recognized as a stop codon during protein synthesis. In the presence of a stem loop 
structure (SeCys element) in the transcribed mRNA, located either downstream the 
UGA codon or at the 3’-end of the gene in prokaryotes and eukaryotes respectively, 
accessory proteins may mediate the binding of the cellular Sec-tRNA to the UGA 
codon and the incorporation of the selenocysteine residue in the nascent peptide [57-
59]. Both in vivo and in vitro experiments have demonstrated that the Sec residue, 
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when present in the active site of glutathione peroxidases, is strictly required for the 
full catalytic activity of the enzymes [60, 61]. 
A few crystallographic data on Gpxs from different classes have elucidated 
some aspects of their macromolecular assembly and clarified the nature of their 
catalytic sites. With the exception of Gpx4, the other isozymes appeared in the 
tetrameric form [62-64] and all of them share the same basic mechanism of action. 
In this respect a detailed computational study recently suggested a model for the 
catalytic mechanism of all selenium-containing enzymes belonging to the Gpx 
family. It is based on a ping-pong mechanism, where the reduction of peroxides by 
Gpx is coupled to the oxidation of the catalytically active form of the enzyme, 
represented by the selenolate anion (E-Se-), to selenenic acid (E-SeOH). Then, in a 
second step two reducing equivalents, usually supplied by two glutathione 
molecules, should recycle the enzyme to its active form passing through a 
selenosulfide intermediate (E-Se-S-G) [65] (Fig. 9).  
 
 
 
 
 
Fig. 9: Proposed mechanism for the catalytic cycle of glutathione peroxidase. The enzyme shuttles 
between the reduced form E-Se- (selenolate anion) and the oxidized one (selenenic acid). The peroxide 
reduction is accompanied by the oxidation of the selenolate to the selenenic acid. Then the oxidized 
enzyme is recycled back to the active reduced form reacting with two molecules of GSH and passing 
through an intermediate selenosulfide adduct (E-Se-SG). 
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The active site of Gpxs from all classes presents some highly conserved 
aminoacidic residues, which may explain the similar mechanism of action. Apart 
from the reactive Sec, a Gln and a Trp residues are also highly conserved, and 
recently it has been demonstrated that an additional Asn residue plays an essential 
role in the catalytic reaction [66]. 
 
1.5.2 The parasite Gpx and its interest for antischistosomal therapy 
The first gene coding for a monomeric Sec containing Gpx (SmGpx-1) was 
cloned in S. mansoni more then ten years ago [67, 68], but a recent analysis of the 
parasite genome lead to the identification of an additional Gpx gene, encoding a 178 
aminoacid protein (SmGpx-2). It shares with the previously discovered SmGpx-1 an 
in-frame UGA codon, coding for the active site Sec residue, and a SECIS element in 
the 3’-non-coding region of the corresponding mRNA, essential for the insertion of 
the Sec residue by the cellular translation apparatus [53]. Both SmGpx-1 and 
SmGpx-2 belong to the class-4 of Gpxs, as proved by the fact that the predicted 
aminoacid sequence of SmGpx-2 has 55% and 48% identity with SmGpx-1 and 
HsGpx-4, but less then 36% identity with other classes of human Gpxs. Indeed the 
main difference between the two Schistosoma enzymes seems to rely in their 
cellular localization. Slight modifications in the sequences of the two proteins, 
related both to aminoacidic substitutions in the C-terminal segment and to the 
presence of an additional N-terminal cleavable peptide in the sequence of SmGpx-2, 
could explain the different cellular targeting of SmGpx previously demonstrated by 
immunolocalization experiments [67, 69]. Thus, though extremely similar, SmGpx-1 
could be directed mainly to the egg vitelline cells of female worms, while SmGpx-2 
should be a secreted enzyme directed to the tegument and gut epithelium [53]. 
Apart from this still questionable difference in the cellular localization, a 
functional characterization of the Schistosoma Gpx has clarified that the enzyme has 
a great similarity with the human Gpx-4 (HsGpx-4), a 20 KDa monomeric enzyme 
highly reactive towards phospholipids and cholesterol hydroperoxides rather than 
towards inorganic peroxides, such as hydrogen and cumene hydroperoxides [50, 51]. 
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Its substrate specificity and the evidence of an association of SmGpx with the 
tegument in adult worms [69], have proved the exclusive role of the Schistosoma 
enzyme in the protection of biological membranes from oxidative damage, making 
on the one side this enzyme a potential druggable target, and on the other hand a 
promising candidate for the design of a vaccine against Schistosomiasis, being 
localized at the host-parasite interface. In this respect preliminary vaccination of 
mice with DNA constructs coding for SmGpx resulted in a worm burden decrease of 
more than 40% if compared with a control group [20], but further efforts are still 
needed in order to localize SmGpx epitopes and/ or to find out specific 
chemotherapeutic drugs. 
 
1.6 The Schistosoma Thioredoxin Glutathione Reductase (TGR) 
1.6.1 Different roles of mammalian and parasite TGRs 
As mentioned above, Thioredoxin Glutathione Reductase (TGR) is a 
flavoprotein belonging to the TR family of pyridine nucleotide oxidoreductases. 
Both mammalian and Schistosoma TGR are homodimeric enzymes, sharing the 
same domain organization but having a very different physiological role. The 
protein results from the fusion of different domains: a big pyridine-disulfide 
oxidoreductase domain, containing both binding sites for FAD and NADPH 
cofactors and a thiol-redox active couple; a small glutaredoxin domain at the N-
terminal end; a dimerization domain in the C-terminal portion of the polypeptide 
chain, at the end of which is located the Gly-Cys-Sec-Gly terminal tetrapetide [70].    
The mammalian TGR has a tissue-specific localization, being overexpressed 
only in testis after puberty, though low levels of the enzyme can be found also in 
other tissues. The main activity of TGR in mammals seems to be a disulfide 
isomerase/reductase: the enzyme catalyzes the isomerization of disulfide bonds in 
proteins, promoting the formation of structural components of sperm [70]. In 
parasites, on the contrary, TGR acts above all as antioxidant enzyme, exploiting a 
key role in redox homeostasis and parasite life-maintenance into the host. A few 
TGR isoforms have been identified in different human parasites, such as T. 
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crassiceps and E. granulosus, all sharing a similar domain organization if compared 
with the mammalian enzyme: a Grx domain fused with a TR domain, which can 
work either coupled or independently from each other. It has been proved in fact, for 
E. granulosus, that the Grx domain can accept reducing equivalents directly by the 
TR domain or by GSH, while the TR domain can shuttle electrons either internally 
to the Grx domain or externally to Trx [71, 72]. 
The first functional characterization of a TGR from S. mansoni  (SmTGR) 
definitively demonstrated that the enzyme completely replaces TR and GR enzymes 
in the parasite, thus stating the peculiarity of the worm detoxification pathway 
relying on a unique multifunctional oxidoreductase and its divergence from the 
human counterpart [48]. The catalytic mechanism of SmTGR has not been fully 
elucidated yet, though a hypothesis already exists for the mouse TGR. The NADPH-
dependent activities of the enzyme seem to be dependent on the penultimate Sec 
residue located at the C-terminal segment of the protein. It is clear in fact that the 
depletion of selenium from diet has a negative effect on the expression of TGR in 
mice and mutations in the C-terminal Sec residues cause a significant decrease in the 
catalytic efficiency of the enzyme [73]. A comparative modeling study on SmTGR 
has recently localized the putative binding sites of substrates and cofactors to the 
enzyme, suggesting a catalytic mechanism that implies some conformational 
transitions during the electron transfer which follows the binding of NADPH to the 
enzyme [74]. In this respect the crystallographic analysis of SmTGR, in both its 
unligated form and in complex with its physiological substrates, have provided a 
pattern of more specific information about the active sites of the enzyme and its 
catalytic mechanism, as will be discussed in detail in chapter 3 [75, 76].  
 
1.6.2 Inhibitors of SmTGR as antischistosomal drugs 
TGR is an essential enzyme for Schistosoma, as highlighted by its particular 
role in the redox homeostasis. There is evidence that its suppression or inhibition 
highly compromises the parasite survival. In fact RNA interference experiments, in 
which a dsRNA was added to schistosomula in vitro in order to silence TGR 
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expression, resulted in the death of 90% of the cultured worms within 4 days and a 
decrease by more than 60% of SmTGR activity after 3 days of treatment. The 
existence of a strict connection between the parasite survival and the catalytic 
activity of TGR enzyme was confirmed by further inhibition assays. Auranofin, a 
potent TGR inhibitor, besides being able to increase the effect of RNAi on worm 
viability, caused unpairing of female and male Schistosomes after 1h and up to 
100% of worm mortality within 9h if added to a concentration of 10µM to cultured 
worms. It is necessary to point out that mammalian cells may tolerate up to 100µM 
of AF for 5 days, while worm death was obtained in 24h at a concentration of 5µM 
of AF. It was also demonstrated that, besides auranofin, SmTGR activity is strongly 
affected by oltipraz and antimonium potassium tartrate, two schistomicidial drugs 
used in the past to fight the infection, suggesting that the enzyme is the main target 
of these compounds [29]. 
Taken together these observations have contributed to raise the interest in 
TGR as a potential target of antischistosomal drugs and recently a quantitative high-
throughput screening of ~71000 compounds was performed to isolate new lead 
compound with schistosomicidal activity. Among them phosphinic amides and 
oxadiazoles 2-oxides were demonstrated to be active against S. mansoni antioxidant 
pathway. The activity of several derivatives of these lead compounds were tested for 
their effect on Schistosoma TGR, on live cultured worms, and in vivo on mice 
infected with the parasite. The most active compound, which even surpassed the 
criteria stated by the WHO for potential lead compound for Schistosomiasis, was 
represented by 4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide, able to inhibit both 
the TR and GR activity of TGR in the low nanomolar range. Moreover S. mansoni 
parasites cultured in the presence of 10 µM of the inhibitor resulted in 100% worm 
death after 24 h, while the administration of the compound by intraperitoneal 
injection to infected mice resulted in a substantial reduction both in worm burden 
and in hepato- and splenomegaly. Because of its protective effect, low cytotoxicity 
in mice, and high effect on the three major species of Schistosoma infecting humans 
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and on the different parasite life cycle stages, furoxan is at the moment considered a 
promising lead compound for the development of antischistosomal drugs [28, 77]. 
Besides the huge number of chemical compounds discovered for their 
schistosomicidal activity, for most of them further research is needed in order clarify 
their mechanism of action and to assess their possible safe employment in the 
treatment of human Schistosomiasis. A few steps towards a better understanding of 
the drug action have been made in the case of furoxan. It has been hypothesized that 
the release of NO by this compound plays a crucial role in its mechanism of action 
Furoxan acts as a NO donor in the presence of TGR, NO may react with the active 
thiols of the enzyme and thus the consequent inhibition could be the result of the 
covalent S-nitrosilation of the active site cysteines and/or selenocysteines. The 
release of NO by furoxan has been also directly related to the worm killing as the 
employment of NO scavengers decreased the activity of the drug [28]. More detailed 
information has been presented for auranofin, at the moment one of the most 
promising antischistosomal drugs. In vitro experiments demonstrated that different 
cultured parasites (Taenia, Echinococcus and Schistosoma) are killed by auranofin 
[29, 78], which has been suggested to be a selective inhibitor of Sec-containing 
oxidoreductases. Indeed the gold-compound has a strong effect on TR and TGR 
activities if used at stoichiometric amounts, whereas 1000-fold higher concentrations 
are required to inhibit GR, which lacks the C-terminal Sec residue, over the same 
time regime of TR [79]. These observations suggested that Sec is crucial for the 
inhibition of reductases by AF, as it has been recently proved by our recent 
structural and kinetic analyses. The C-terminal Sec residue of TGR should facilitate 
the undressing of gold from its ligands in AF (the thioglucose and the 
triethylphosphine) given its higher nucleophilic power than sulphur. The gold atom 
(Au+1) binds at first to the final Sec-Cys redox center of the enzyme and then it is 
transferred to the other couples of reactive cysteines leading to formation of gold-
protein thiols adducts, which finally inhibit the catalytic activities of the enzyme 
[80]. 
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2. AIM OF THE WORK 
 
Targeting the Schistosoma antioxidant detoxification pathway is among the 
topics of current researches for new antischistosomal therapies. This pathway is 
responsible for the detoxification of reactive oxygen species produced by the host in 
response to the parasite invasion, and it is thus essential for the survival of 
Schistosomes into the human host. This work is aimed to characterize two enzymatic 
components of the worm detoxification pathway, i.e.: Glutathione Peroxidase 
(SmGpx) and Thioredoxin Glutathione Reductase (SmTGR). 
Glutathione peroxidases (Gpx) are a family of sulfur or selenium-dependent 
isozymes sharing the ability to reduce peroxides using the reducing equivalents 
provided by glutathione or possibly by small proteins such as thioredoxin. SmGpx is 
one of the frontline antioxidant defenses of the parasite, being localized in the worm 
tegument, the outermost defense layer. A few structures of oligomeric Gpxs already 
exist from different organism but less is known about the class 4 monomeric Gpxs, 
whom the Schistosoma enzyme belongs to. In this work the first crystal structure of 
two recombinant SmGpxs, carrying the active site mutations U43C and U43S 
respectively, will be presented. The geometry of the active site of the U43C SmGpx 
and the organization of residues surrounding the catalytic cysteine will be explored, 
based on the details provided by an atomic resolution crystal structure of the U43C 
mutant. Moreover a comparison with the human Gpx4 (HsGpx4) recently 
characterized will allow to investigate the peculiar reactivity of the parasite enzyme, 
whose active site Cys undergoes spontaneous oxidation to sulfonic acid, not reported 
for the same Sec/Cys mutant of HsGpx4. To test whether the oxidation of Cys43 to 
the bulkier sulphonic acid altered the structure of SmGpx, the structure of the U43S 
mutant will be solved as well. Indeed the U43S mutant of SmGpx maintains the 
same 3D structure of the U43C mutant, thus strongly suggesting that the oxidation 
of Cys43 does not perturb significantly the native structure of the enzyme. Given the 
absence of any structure of Gpx in its ligated form, a combined analysis of the static 
and dynamic clefts close to the catalytic C43 in the U43C mutant will be performed, 
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by mean of the CASTp algorithm and the molecular dynamic simulations, 
respectively. The functional relevance of the identified clefts and the conformational 
changes relevant to catalysis will be discussed in order to give some hints about the 
putative binding site for glutathione and phospholipid hydroperoxides, the substrate 
of choice for SmGpx, being the enzyme membrane-associated and involved in the 
detoxification of lipid peroxides more than H2O2 and inorganic peroxides. 
Thioredoxin glutathione reductase (SmTGR) is a key flavoenzyme expressed 
by Schistosomes and derived from the peculiar fusion of a glutaredoxin domain with 
a thioredoxin selenocysteine (Sec)-containing reductase domain. It basically links 
two detoxification pathways (the glutathione and the thioredoxin pathways), both 
essential for the protection of the worm from oxidative stress. The silencing of the 
gene coding for SmTGR has been demonstrated to seriously compromise the 
parasite life-maintenance inside the mammalian host, hence this enzyme has become 
one of the most appealing drug targets against Schistosomiasis. A characterization of 
SmTGR by mean of X-ray crystallography will be here presented highlighting the 
structural basis for the multienzymatic function of this enzyme, which is able to 
exploit either thioredoxin reductase, glutathione reductase and glutaredoxin-like 
activities, thus fully replacing TR, GR and Grx mammalian enzymes. Two mutants 
have been employed in this work, the former lacking the two last residues (U597 and 
G598), belonging to the C-terminal G-C-U-G tetrapeptide, and the latter carrying the 
U597C mutation in the C-terminal segment. The C-terminus of SmTGR, as already 
pointed out for TR enzymes from different organisms, has a key role in the catalytic 
activity of the enzyme, thus the comparison between the functional properties of the 
two recombinant enzymes will give some hints in this respect. It is already known 
that, similarly to mammalian TR, SmTGR is able to accept reducing equivalents 
from NADPH, and electrons then will flow through the enzyme and will reach either 
the GSH reducing site, the glutaredoxin domain or the SmTrx reducing site. The 
U597 mutant has been crystallized in different redox states (i.e.: the oxidized form; 
the NADPH- and GSH-bound forms; and a species showing the entire and ordered 
C-terminus of one subunit fully reduced) in order to obtain insights into the 
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structural changes associated with the progression of the enzyme through the 
catalytic cycle. These structural observations combined with two models showing 
SmTGR in the act of transferring electrons to SmTrx and to the Grx domain, will 
assign a critical role to the C-terminus of the protein, which mediates the 
interdomain communication in SmTGR and seems to act as a flexible arm able to 
switch between different positions while transferring electrons either to the Grx 
domain of SmTGR or to the external SmTrx substrate. The possible function of this 
peculiar parasitic enzyme, which is absent in the free-living non-pathogenic species 
of the same platyhelminth phylum, will be finally discussed. 
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3. MATERIALS AND METHODS 
 
I part: Glutathione peroxidase from S. mansoni (SmGpx) 
 
3.1 Mutagenesis 
The U43C SmGpx gene, with codons optimized for E. coli expression 
(GeneArt AG, Germany), was cloned between BamHI and XhoI restriction sites of a 
pGex4T-1 expression vector (GE Healthcare) to obtain a GST-fusion protein. In 
order to obtain the second recombinant mutated protein U43S, a mutagenesis 
experiment was carried out using the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene). The U43C SmGpx expression vector was used as template and the 
following oligonucleotides containing the mutated serine codon AGC were 
synthesized (Primm srl, MI-Italy) and used as primers: 
For: 5’-CGTGGCGTGCAAAAGCGGCGCGACCG-3’ 
Rev: 5’-GCACCGCACGTTTTCGCCGCGCTGGC-3’ 
 
3.2 Protein expression 
The plasmids containing the genes coding for both the GST-fused U43C and 
U43S mutant of SmGpx were used to transform Escherichia coli BL21(DE3) cells 
(Novagen), which were then plated onto LB/Agar plates containing 100µg/ml 
ampicillin (Amp). One colony was used to inoculate 5ml LB/Amp, grown overnight 
at 37 ºC with shaking. This culture was used to further inoculate 1lt LB/Amp, which 
was incubated at 37 ºC with shaking until an optical density of 0.5 Abs at 600 nm 
was reached. The expression of the soluble protein was obtained after the addition of 
0.5 mM IPTG and overnight incubation at 25 ºC with shaking. 
 
3.3 Protein purification 
Two methods were used for the purification of recombinant U43C SmGpx, so 
after centrifugation the cells were divided into two stocks. Lysis buffer composed of 
20mM Tris/HCl, 0.2M NaCl, 5mM TCEP, 0.1% TrytonX-100, DNase, 1mM PMSF, 
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1mM EDTA, pH 7.4 was added to one of the two samples before sonication. U43C 
SmGpx was purified from the soluble fraction through affinity chromatography 
using a GSH-Sepharose column (GE-Healthcare), and GST was cleaved with bovine 
thrombin (Sigma). The second protein sample was purified by ionic exchange 
chromatography. The purification was performed adding 10mM GSH to the lysis 
buffer to assure the maintenance of a reduced environment both during cell lysis and 
protein purification. To purify the protein, after sonication, the soluble fraction was 
applied on a HiTrap SP FF column (GE-Healthcare) equilibrated with the starting 
buffer 20mM Tris/HCl, 20mM NaCl, 5mM TCEP, 5mM GSH, 1mM EDTA, pH 
7.4. U43C protein was eluted by continuous salt gradient using a second buffer with 
a higher ionic strength (100mM Tris/HCl, 0.5M NaCl, 5mM TCEP, 5mM GSH, 
1mM EDTA, pH 7.4). The eluted protein was then cleaved with bovine thrombin. 
Recombinant U43S protein was purified through GST-affinity chromatography, as 
described previously for U43C SmGpx. For each purification the purity of the 
protein was assessed through overloaded SDS-PAGE, showing a single band 
corresponding to 19.4 KDa. The purified protein was then dialyzed in 20mM 
Tris/HCl, 0.1M NaCl, 1mM DTT, 0.5mM EDTA, pH 7.4, concentrated by 
ultrafiltration (Amicon) and stored at -20˚C. 
  
3.4 Size exclusion chromatography 
U43C SmGpx assembly was assayed by gel filtration in HPLC with a 
Superdex75TM column (GE Healthcare). The protein was concentrated up to 5mg/ml 
and a sample volume of 100µl was applied to the column, which was run at 0.4 
ml/min flow. The following buffer was used 20mM Tris/HCl, 0.1M NaCl, 1mM 
DTT, 0.5mM EDTA, pH 7.4. 
 
3.5 Enzymatic assays 
The activity of U43C and U43S SmGpx was assayed in a coupled reaction 
with yeast glutathione reductase (GR; Sigma), measuring the decrease of A340 as a 
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consequence of the reduction of the hydroperoxide by U43C protein. The assay 
mixture, composed of 1µM U43C SmGpx, 0.2mM NADPH, 3mM GSH, 1 unit of 
GR, in 20mM Tris/HCl, 0.1M NaCl, pH 7.4, was incubated for 5 minutes at 25 °C. 
The reaction started with the addition of 100µM tert-butyl-hydroperoxide or 
hydrogen peroxide. 
 
3.6 Protein crystallization 
3.6.1 Basic procedure 
Vapor diffusion is the most frequently used technique for protein 
crystallization and basically consists in allowing a slow and controlled precipitation 
of the protein in order to obtain ordered crystals instead of amorphous precipitate. 
An equal volume of protein solution and crystallization solution (reservoir), 
containing the appropriate precipitant at a concentration just below that necessary to 
precipitate the protein, are mixed to form a drop (Fig. 10). The drop containing the 
protein/reservoir mix is allowed to equilibrate in a closed container with a large 
volume of reservoir solution (Fig. 10). Being the [precipitant] in the drop equal to 
50% of the [precipitant] in the reservoir solution vapor diffusion (evaporation and 
condensation) results in the net transfer of water molecules from the drop to the 
reservoir, until the equilibrium is reached. At this point both the [protein] and the 
[precipitant] in the drop have increased and the first nuclei of crystallizations form in 
the drop (nucleation region in Fig. 11). In a perfect system as the crystal grow the 
[protein] gradually decreases and the conditions move towards those of the “growth” 
region (growth region in Fig. 11) allowing the formation of a big crystal. 
Vapor diffusion can be obtained through two different methods depending on 
the position of the protein/precipitant drop with respect to the reservoir solution: the 
hanging drop and the sitting drop. In hanging drop, the drop is suspended on a cover 
slip over a sealed reservoir, containing the crystallization solution; in sitting drop, 
the drop is held in a microbridge in the centre of the reservoir (Fig. 10). In both 
cases vapor diffusion occurs between the drop and the reservoir solution until an 
equilibrium is reached, during which one hopes to bring the protein to 
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supersaturation and hence crystallization conditions (Fig. 11). Protein purity, 
[protein] and [precipitant], as well as pH of the protein/reservoir solution and 
temperature are among the variables that determine the success of a crystallization 
experiment. 
 
 
 
 
 
Fig. 10: Vapor diffusion by: (a) hanging drop and; (b) sitting drop crystallization. The reservoir contains 
the crystallization buffer and the precipitant; the drop hanging from the cover slip or sitting on the 
microbridge contains the protein/reservoir solution. 
  
 
 
 
 
 
Fig. 11: Phase diagram for crystallization mediated by a precipitant. In the undersaturated zone the 
solution is not saturated with the protein so neither nucleation nor growth may occur. Inside the 
supersaturated zone the regions in which the [protein] and [precipitant] are optimal for nucleation and 
growth of protein crystals are shown. Conditions inside the precipitation zone lead to the formation of 
amorphous precipitate rather than ordered protein crystals. 
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3.6.2 Crystallization of U43C and U43S SmGpx 
Crystals of SmGpx were grown by vapor diffusion according to sitting drop 
methods. A solution of 15 mg/ml U43C or U43S SmGpx was used to screen the 
crystallization conditions by mean of an automated robotic system (Phenix, Art 
Robbins). Refinement of the crystallization conditions was done by hand in sitting 
drop vapor diffusion 24-well plates, with symmetric drops of 1 µl each of protein 
solution and reservoir After 4 days crystals of U43C mutant were obtained in the 
drops with the following well solution: 0.2M LiSO4, 0.2M Na Acetate, 24% PEG 
8000, pH 4.5. A longer time of 7 days was required to obtain good crystals of U43S 
SmGpx using a well solution of 0.2M NaH2PO4, 0.1M MES, 32% PEG-MME 5000, 
pH 6.0. 
 
3.7 Data collection, processing and refinement 
X-ray data collection was performed at the synchrotron beamline ID29 at 
ESRF (Grenoble, France) with an ADSC Q315R detector for U43C SmGpx, while 
data collections of U43S crystals were performed at the synchrotron beamline 
ID14.2 at BESSY (Berlin, Germany) with a MARCCD detector. All data were 
indexed with Mosflm and processed with programs of the CCP4 Suite [81]. U43C 
mutant crystallized in a P212121 space group with cell dimension of a= 41.40 Å, 
b=60.62 Å, c=62.54 Å, α=β=γ=90º, and 1 molecule in the asymmetric unit.  
The structure was solved by molecular replacement using human HsGpx4 as 
model (PDB code: 2OBI, [63]). U43S mutant showed the same space group but 
slightly different cell dimensions of a=39.91 Å, b=51.17 Å, c=90.62 Å, α=β=γ=90º. 
In this case the structure of U43C SmGpx was used as model for the molecular 
replacement. Molrep and Refmac programs were used respectively for the molecular 
replacement and the successive refinements [81]; the structures were built using 
COOT [82]. Figures were produced with CCP4mg [83]. The quality of the models 
was assessed with MolProbity [84] and ProCheck [85]. Data collection and 
refinement statistics are summarized in tab. 1. The structures were deposited at 
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RCSB Protein Data Bank (U43C SmGpx PDBcode: 2v1m; U43S SmGpx PDBcode: 
2wgr). 
 
3.8 Sequence alignment 
The ClustalW2 [86] server was used to obtain a multiple alignment between 
SmGpx1-2, HsGpx1-4 and BtGpx1 sequences, extracted from NCBI protein 
sequence database. The alignment files obtained with ClustalW have been visualized 
with ESPript [87]. 
 
3.9 Surface analysis 
In order to look for static cleft and/or cavities to detect GSH and phospholipids 
binding sites the deposited coordinates were analyzed with the online program 
CASTp (http://sts-fw.bioengr.uic.edu/castp/index.php), using the server default 
value of 1.4 Å as probe radius. 
 
3.11 Docking 
Molecular docking was performed using the PatchDock algorithm [91]. Two 
files of coordinates, for SmGpx (2v1m) and for the phosphatidylcholine (CPL), 
enriched with hydrogen atoms, were used as input for the program. After setting the 
RMSD to 9, PatchDock output was a list of potential protein-ligand complexes, 
among which we choose the solution with the highest geometric shape 
complementarity score. 
 
3.10 Molecular Dynamic (MD) simulations 
The MD simulations, included in this thesis for sake of completeness, have 
been performed by Dr M. Anselmi and Prof. A. Di Nola of the Dep. of Chemistry of 
the University of Rome “Sapienza”. 
The starting coordinates employed for the simulations were taken from the x-
ray structure at 1.0 Å resolution of the U43C mutant of S. mansoni Gpx, replacing 
the sulfonic SO3- group with the Se- or SeOH group. Thus the selenocysteine (Sec) 
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in reduced wild type Gpx was modeled as deprotonated, while selenenic derivative 
(SeOH) in oxidized Gpx was considered as protonated. In order to determine the 
partial charges of Sec and its selenenic derivative (SeOH) we performed the 
quantum chemical calculations on the isolated ethyl selenolate (CH3CH2Se-) and 
methyl selenenic acid (CH3SeOH), respectively. Density functional calculations, 
Becke's three parameters exchange [92], and Lee, Yang, Parr correlation (B3LYP) 
[93] were performed using the Ahlrichs VTZ basis set [94]. All quantum chemical 
calculations were carried out using the Gamess US package [95]. Partial charges 
were obtained from the CHELPG algorithm [96]. The same calculations were 
performed on analogues, as ethanol or ethanthiol, in order to test the reliability of the 
procedure, obtaining partial charges in agreement with the force field used.  The 
following set of partial charges were chosen: for selenolate group of Sec, -0.85 e for 
the Se atom and -0.15 e for the Cβ atom, while for selenenic group of the Sec 
derivative, 0.2 e for the Se atom, -0.65 e for the O atom and 0.45 e for the H atom. 
Non-bonded parameters for selenium were set to σ = 0.458 nm and ε = 1.154 kJ/mol 
[97]. The force constants of bonded interactions for selenium were taken to be 
identical to those for sulfur while the equilibrium values were changed. In particular 
we set the C-Se bond to 1.95 Å, the Se-O bond to 1.82 Å, the C-C-Se angle to 108°, 
the C-Se-O angle to 97° and Se-O-H angle to 116°. 
Each protein was solvated in a box with explicit SPC water molecules [98]. 
Three Cl- for Gpx(Se-) and four Cl- for Gpx(SeOH) were added, in order to provide 
a neutral simulation box. For all systems, the solvent was relaxed by energy 
minimization followed by 50 ps of MD at 293 K, while restraining protein atomic 
positions. The systems were then minimized without restraints and their temperature 
brought to 293 K in a step-wise manner, before starting the production runs of 30 ns. 
MD simulations were performed with the Gromacs software package [99] using 
GROMOS96 force field [100]. Simulations were carried out at constant temperature 
of 293 K. The Lincs algorithm [101] to constrain bond lengths and the 
rototranslational constraint algorithm [102] were used. The temperature was held 
constant by the isothermal algorithm [103]. The Particle Mesh Ewald (PME) method 
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[104] was used for the calculation of the long-range interactions. A time step of 2 fs 
was used. We used the essential dynamics technique [102] to characterize the 
dynamical behaviour of the protein. The package SURFNET [105] was used for 
detecting the clefts on the protein surfaces and estimating their volumes. Cavity 
volumes were evaluated without taking into account the presence of water 
molecules. 
 
II part: Thioredoxin Glutathione Reductase from S. mansoni (SmTGR) 
 
3.12 Mutagenesis 
The gene for the full-lenght SmTGR with the mutation U597C (U597C 
SmTGR), was obtained starting from the gene of truncated SmTGR (SmTGRtr) 
lacking the last two amino acids Sec597-Gly598 optimized for E. coli expression 
(GeneArt AG), with appropriate DNA primers.  
For: 5’-GATCGGATCCCCGATGCCGCCGGCAGATGGC-3’ 
Rev: 5’-ACTCGCCGACGACGCCGATTATTGAGCTCGCC-3’ 
Both genes were cloned in a pGEX4T-1 commercial vector (GEHealthcare) 
between BamHI and XhoI restriction sites. 
 
3.13 Protein expression and purification 
Both the SmTGRtr and the U597C SmTGR mutant were expressed in 
BL21(DE3) E. coli cells (Novagen). The best results, in terms of solubility and 
protein yield, were obtained upon induction at 22°C with 1 mM IPTG in the 
presence of 1 mM FAD for SmTGRtr, while the soluble full-length SmTGR was 
obtained at 20°C overnight with 50µM FAD, without IPTG induction. In both cases 
successful expression was confirmed by SDS-PAGE, highlighting a band at about 
90 kDa. The protein was purified by standard affinity chromatography; the GST tag 
was cleaved by thrombin (Sigma) and removed according to manufacturer’s 
instructions. Protein purity was >98% as assessed by SDS-PAGE, and concentration 
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was determined from the FAD absorption peak (ε463 = 11.3 mM-1 cm-1). Both 
proteins were dialyzed in 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 100µM FAD (to 
saturate the enzyme), concentrated up to 10 mg/mL using an Amicon Ultra 
centrifuge filter device (Millipore) and stored at -80°C. 
 
3.14 Protein crystallization 
3.14.1 Truncated SmTGR 
Crystallization conditions were initially screened by Phoenix nanolitre 
dispensing robot (ArtRobbins, USA) and then refined according to standard hanging 
drop methods. Crystals of SmTGR grew over 2 days in a drop composed of 1 lL 
protein (15 mg/mL) and 1 lL well solution (22% (w/v) PEG 3350, 0.1M Hepes pH 
7.2, 0.2M NaNO3, 5 mM DTT, or b2ME). 
 
3.14.2 Oxidized U597C SmTGR (Structure 1) 
A crystal of U597C SmTGR, grown in Hepes 0.1M pH7.4, 20% PEG 3350, 
KI 0.2M and β-mercaptoethanol 5mM, was picked up and incubated in the same 
well solution with 2µM CuSO4 and without β-mercaptoethanol. After 48h, the 
crystal was freezed under liquid nitrogen, after adding 30% PEG 200 as 
cryoprotectant. 
 
3.14.3 U597C SmTGR-NADPH complex (Structure 2) 
120µM of purified U597C SmTGR in 20 mM Tris, pH 7.4, 100 mM NaCl was 
initially incubated for 24 hours with 300µM plumbagin (SIGMA), 400µM NADPH, 
in anaerobiosis condition. The mixture was then concentrated to 10mg/mL before 
crystallization trials set up. The protein solution was mixed with an equal amount of 
the reservoir solution containing 0.1 M Hepes at pH 7.0, 20% PEG 3350, 0.2M 
KSCN, and 5 mM GSH. Crystal grew in 1 month in standard sitting drop method 
and were cryoprotected with the same reservoir solution adding 30% PEG 200. 
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3.14.4 U597C SmTGR with reduced C-terminal end (Structure 3) 
Crystallization conditions were initially screened by the Phoenix nanoliter 
dispensing robot (ArtRobbins) and then manually refined. Crystallization was 
achieved at 293 K by the sitting drop vapor diffusion technique. 10 mg/mL protein 
sample were equilibrated in 1mM NADPH in 20 mM Tris-HCl, 100mM NaCl 
pH7.4. Drops of 2µL were mixed with an equal amount of the reservoir solution 
containing 0.2M Mg-formiate, 20% PEG 6000, 0.1M Hepes at pH 7.0-7.5 plus 5mM 
β-mercaptoethanol. Crystals grew in 1-2 weeks and were cryoprotected with the 
same reservoir solution adding 30% PEG 200. 
 
3.14.4 U597C SmTGR-GSH complex (Structure 4) 
Crystals were grown by sitting drop vapor diffusion. Crystals grew in 
conditions similar to those of oxidized U597C SmTGR (See above). 5mM GSH 
replaced β- mercaptoethanol. Crystals grew in 1 week and were cryoprotected with 
the same reservoir solution containing 30% PEG 200. 
 
3.15 Data Collection, Processing and Refinement 
3.15.1 Structure 1, Structure 2 and Structure 4 
The best data sets for the oxidized and for the NADPH-bound form and for the 
of SmTGR(U597C) have been collected at BESSY (Berlin, German) at 100K at 1.9 
and 2.3Å resolution, respectively; while for the GSH-bound form the best dataset 
was collected at ESRF at 1.9Å resolution. Data analysis was performed with 
HKL2000 suite [106] indicating that all crystals belonged to the C2 space group. 
Difference Fourier method was used to solve all structures and refinements were 
performed using REFMAC5 [81]. When present, NADPH and GSH were excluded 
from the first rounds of refinement and added only after convergence of R and Rfree 
factors. COOT [82] was used to build all the models of protein and ligands. The 
quality of the model was assessed with ProCheck [85]. Data collection and 
refinement statistics are summarized in tab. 4. The structures were deposited at 
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RCSB protein data bank (PDB codes: 2X8G for the oxidized form; 2X99 for the 
NADPH complex; and 2X8H for the GSH complex). 
 
3.15.2 Structure 3 
Diffraction data were collected at 3.1Å resolution at Bessy (Berlin, Germany) 
and analyzed using the HKL2000 suite [106]. The 3D structure was solved by 
molecular replacement [81] using as a search model one protomer of truncated 
SmTGR structure (PDB code: 2v6o) [75]. The structure was refined using 
REFMAC5 and fit to the generated electron density maps using Coot [82]. 
Refinement was performed until a final R/Rfree of 22.0% and 29.3% respectively was 
reached. The final model showed one dimer in the asymmetric unit with a FAD 
molecule bound to each subunit. The quality of the model was assessed with 
ProCheck [85]. The statistics of crystallographic data collection and model 
refinement are shown in tab. 4. The structure was deposited at RCSB protein data 
bank (PDB code: 2X8C). 
 
3.16 Modeling 
3.16.1 Model 1: the C-terminus of U597C SmTGR onto the Grx domain 
The C-terminal residues, C597 and G598, visible in Structure 3, were 
superimposed to the Cys and Gly residues of the GSH bound to the Grx domain in 
the GSH-bound form of the SmTGR (Structure 4). The model was obtained mainly 
by rotation of the C-terminal arm at the level of K586 psi angle. Small adjustments 
of the main chain were performed in order to obtain the best superposition of the last 
two residues of the protein with the analogue residues of the bound GSH, avoiding 
clashes between amino acid side chains. Idealization of the model (Refmac5, [81]) 
was done at the end to ensure the absence of unfavourable contacts between atoms. 
The model, after optimization, was evaluated with PROCHECK [85]. 
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3.16.2 Model 2: the SmTGR-SmTrx complex 
A model of a plausible complex between the structure of SmTrx (pdb code: 
2XBI) and Structure 3 of U597C SmTGR (pdb code: 2X8C) was obtained using a 
rigid body method with shape complementarity. The structures were used as input 
for the SUMMA server [107]. The server has calculated the best complementary 
surface and was told to freely perform energy minimization only on SmTGR C-
terminal arm (residues 509-598) and on the active site stretch of SmTrx (residues 
33-38). Idealization of the model was automatically performed at the end to ensure 
the absence of unfavourable contacts between atoms. A S-S bond was built between 
SmTrx C34 and SmTGR C596 with rotamers compatible with the reduced SmTrx 
protein. 
 
3.17 Kinetic measurements 
3.17.1 TR activity 
Both the 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB) reduction assay and the 
insulin reduction assay were performed. For the DTNB assay [108] SmTGR (0.5 
µM) was added to a mixture of 100 mM potassium phosphate pH 7.0, 10 mM 
EDTA, 0.2-5 mM DTNB and 300 µM NADPH at 25°C. The increase in absorbance 
at 412 nm was monitored (ε412= 13.6 mM-1cm-1). For the insulin assay the 
absorbance at 650 nm was measured after addition of U597C SmTGR (0.5 – 2.5 
µM) to a reaction mixture composed by 50 mM K-phosphate pH 7.0, 200 µM 
NADPH, 1 mg/ml insulin, and 9 µM of SmTrx. Stock solutions of insulin were 
prepared as previously described [109]. Insulin precipitation after reduction by Trx 
was followed spectrophotometrically according to [109]. As control, the 
precipitation of insulin was performed using dithiothreitol (DTT) as the reducing 
agent. The time for the start of precipitation, defined as an increase by 0.02 at A650 
over a stable base-line recording, was determined. The second parameter calculated 
was the rate of precipitation at 650 nm, defined as the maximal increase ∆A650/min 
in the interval between 0 and 1.0 in absorbance at 650 nm. 
 
Chapter 3 
 
43 
3.17.2 GR activity 
A classical assay was performed [110]. 1ml assay mixture contained 150mM 
potassium phosphate pH 7.0, 5 mM EDTA, 300 µM NADPH, and variable GSSG 
(250 µM-5 mM). The reaction was initiated by addition of 2.5 µM U597C SmTGR 
and the decrease in absorbance at 340 nm was followed at 37°C. 
 
3.17.3 Grx activity 
The assay was performed as described (by monitoring absorbance at 340 nm, 
at 25°C, [111]). The mixed disulfide formed by hydroxyethyl-disulfide (HED) and 
GSH was reduced by U597C SmTGR to produce GSSG, which in turn is reduced by 
GR with consumption of NADPH. The reaction mix contained 1 mM GSH, 300 µM 
NADPH, 5 mM EDTA, and variable HED with or without 6 U/ml of yeast GR. The 
same assay has been performed in the absence of yeast GR to evaluate the ability of 
the mutated C-terminus to internally transfer reducing equivalents to the Grx 
domain. 
 
3.17.2 Reductive half-reaction of U597C SmTGR 
Stopped-flow experiments were carried out using an Applied Photophysics 
(Leathered, UK) in aerobic conditions at 25°C.  
The stopped-flow apparatus allows the rapid mixing of two reactant solutions 
(Fig. 12). The mixed solution is then forced through an observation cell and a 
stopping syringe. The flow fills the stop-syringe, until the plunger hits the trigger-
switch. This simultaneously stops the flow and starts the data acquisition. The 
sample is illuminated by light at fixed wavelength, and the outcoming radiation is 
collected and amplified by a photomultiplier. The reaction may be monitored using a 
suitable spectroscopic probe, such as absorbance or fluorescence. The change in the 
spectroscopic signal as a function of time is recorded.  
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Fig. 12: Schematic representation of a stopped-flow apparatus. 
 
 
In the case of the reaction of reduction of SmTGR by NADPH, time dependent 
spectra were followed using the diode array detector and single-wavelength kinetic 
traces were recorded with a photomultiplier. Solutions of SmTGR (2.5 and 7.5 µM) 
in 0.1 M NaCl, 0.1 M Tris pH7.4 and EDTA 1mM were mixed with several 
NADPH solutions, ranging between 3.3 µM and 20 µM. 
 
3.17.3 Oxidative half-reaction of U597C SmTGR 
SmTGR (3.0 µM, 5 µM and 10 µM) were anaerobically reduced with 2 
equivalents of NADPH to produce the EH4 species, at 25C° in 0.1 M NaCl, 0.1 M 
Tris pH 7.4, EDTA 1 mM. The reduced enzymes were then mixed with 2 
equivalents of SmTrx and the reactions were followed until completion. 
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4. RESULTS AND DISCUSSION 
 
I part: Glutathione peroxidase from S. mansoni (SmGpx) 
 
4.1 Expression and purification of two mutants of SmGpx 
SmGpx in its native form is a selenoenzyme, presenting a SeCys residue (U43) 
in the active site. For this study two mutants of SmGpx have been employed, which 
present a Sec/Cys (U43C) and a Sec/Ser (U43S) aminoacidic substitution 
respectively. This strategy was mainly dictated by the fact that the synthesis of 
recombinant selenoproteins does not assure a good yield especially if it deals with 
the expression of eukaryotic proteins in bacteria. A brief description of the 
mechanism of selenoprotein synthesis will clarify this statement. The insertion of a 
Sec residue in a protein sequence during translation in eukaryotic cells requires the 
presence of a stem-loop secondary structure (SE-CYS element) in the 3’-UTR 
region of the mRNA, besides a pattern of accessory proteins and specific tRNA 
molecules, which are able to recognize the UGA codon as coding for a SeCys 
residue. Differently from eukaryotes, in bacteria the SE-CYS element must be 
located directly downstream the UGA codon for the Sec residue. Thus, the 
heterologous expression of a eukaryotic gene in bacterial cells strictly requires a 
modification inside its coding sequence, which seriously compromises the yield and 
the purity of the protein product [58, 59, 70]. Therefore with the aim to obtain large 
amounts of recombinant protein for crystallization studies we decided to synthesize 
the U43C mutant. The gene of U43C SmGPX was inserted, between BamHI and 
XhoI restriction sites, into a pGex4T-1 expression vector, which allows the addition 
of a thrombin-cleavable N-terminal GST tag. After the thrombin cleavage the 
protein contains two additional residues at the N-terminus (Gly-Ser) that constitute 
part of the cleavage site (Fig. 13). 
A point-mutagenesis on the U43C construct allowed us to obtain the gene 
coding for the U43S SmGpx (see Chapter 3). The expression of both mutants of 
SmGpx in E. coli BL21(DE3) strand was evaluated by SDS-page, showing a clear 
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band around 19.4 KDa (after the thrombin cleavage), which corresponds to the 
expected molecular weight of the pure protein (Fig. 14). 
 
 
 
 
 
Fig. 13: Map of the pGex4T-1 expression vector. The thrombin cleavage site, placed downstream the GST 
gene, is shown. 
 
 
 
 
 
 
Fig. 14: SDS-Page showing the expression of U43C SmGpx after the IPTG induction. Lanes 1: 
supernatant after sonication of the cell extract; 2: pellet after sonication; 3: flow through containing the 
material unbound to the GST-affinity column; 4: U43C SmGpx eluted by the GST-affinity column after 
thrombin cleavage; 5: U43C SmGpx after the benzamidine column, which is required to remove 
thrombin; 6: elution from the GST-affinity column with 10 mM GSH, the amount of the GST band around 
26 KDa is comparable to the eluted SmGpx in lane 4. The eluted U43C SmGpx has a M.W. of 19.4 KDa 
and is well purified from contaminants in the final step (lane 5). The molecular weights of the protein 
markers (lane M) are shown on the right side of the gel.   
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4.2 Structural characterization of U43C and U43S SmGpx  
The following sections will describe the overall structure of two SmGpx 
mutants (U43C and U43S), with insights into the interaction sites of the enzyme 
with its substrates. A few structures of isozymes from the Gpx family are available, 
the most of them belonging to the class 1 and 3 of tetrameric Gpxs [62, 64]. A 
Sec/Cys mutant of the human Gpx4 (HsGpx4), the unique member of the Gpx4 class 
to be structurally characterized [63], will be here used as a comparison model in 
order to highlight and explain some special features of the parasite enzyme. 
 
4.2.1 Analysis of the primary structure of SmGpx 
The multiple sequence alignment between SmGpx and Gpxs from all four 
main classes highlights some peculiarities of the schistosoma enzyme. Though 
SmGpx retains the catalytic residues known to be invariant in the other Gpxs 
(Sec43, Gln78, Trp132, and Asn133, [66]), it lacks the conserved residues 
apparently involved in GSH binding (Arg57, Arg185, and Met147 in bovine Gpx, 
[62]) and presents two large gaps corresponding to the intersubunit interaction sites 
of the tetrameric mammalian Gpx1-3 (i.e.: residues 94-98 and 136-153 in HsGpx1) 
(Fig. 15). These features of the primary structure, consistently with gel-filtration and 
analytical ultracentrifugation measurements (data not shown), confirmed the 
monomeric nature of the schistosoma enzyme, clearly assigning it to the class 4 of 
Gpx family. Sayed et al. proposed that S. mansoni has a second variant of SmGpx 
enzyme, called SmGpx2 [53] (see section 1.5.2). The sequence alignment of SmGpx 
with SmGpx2 shows that the two proteins share the same above mentioned sequence 
features, thus proving that the parasite finally possesses only a type-4 Gpx isozyme 
(Fig. 15). 
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Fig. 15: Sequence alignment of SmGpx with Gpx of all classes. Identical residues are boxed in red, 
conserved residues are shown in red character. Sm, Schistosoma mansoni; Hs, Homo sapiens; Bt, Bos 
taurus. 
 
 
4.2.2 Overall 3D structure of U43C and U43S SmGpx mutants  
The crystal structure of U43C SmGpx was solved by molecular replacement 
(see Chapter 3) using the structure of human Gpx4 (HsGpx4) as model (PDB code: 
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2OBI; [63]). A summary of the crystallographic parameters is presented in tab. 1. 
The diffraction data, collected up to 1.0 Å resolution, were refined to the final Rfactor 
and Rfree values of 17.5% and 18.4%, respectively. The validation programs [84, 85] 
showed a very good final geometry and density fit, with all residues lying in the 
preferred regions of the Ramachandran plot. The flexibility of the molecule is 
extremely limited and only nine side chains are placed in alternative conformations. 
The average B-factor is 6.29 Å2, with slightly higher values restricted to the ill-
defined side chains of a few superficial Lys. The high resolution made easier the 
identification of the correct positioning of great part of the polypeptide chain, with 
the exception of the N-terminal region, where a weak electron density map 
prevented us from adding the first six residues to the model.  
U43C SmGpx appears in a monomeric form and shows only a few differences 
with the typical Trx fold, characterized by 4 β strands flanked by 3 α helices [112]. 
U43C SmGpx presents, in fact, a N-terminal extension including two more β strands 
and an insertion with one more β strand and one α helix. For the sake of 
consistency, these secondary structure elements are named β1a, β1β, β2a and α1a. 
A comparison between the topological diagrams of a typical Trx and SmGpx is 
presented in Fig. 16. The central β sheet of U43C SmGpx contains four β strands: 
two of them (β3, β4) are antiparallel and connected to the C-terminal helix α3 to 
form the typical ββα Trx motif; the other two parallel strands (β1, β2) flank helix 
α1
 
to form a βαβ structural motif. Helix α2, perpendicular to α1 and α3, connects 
β2
 
and β3 strands through a linking region containing the additional α1a and β2a 
motifs. Far from the central core and closer to the N-terminal region, the topological 
diagram shows the last structural motif of U43C SmGpx composed by two 
antiparallel β strands (β1a, β1b) (Fig. 16 and 17A). 
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Fig. 16: Topological diagrams for Trx fold (left) and Gpx fold (right), redrawn from [112].  The blue lines 
indicate the loops preceding and following helix α2, related to the fluctuations of the putative GSH 
binding site (see section 4.2.4); the orange box indicates the position of OCS43. 
 
 
 Data collection U43C SmGpx U43S SmGpx 
Space group  P212121 P212121 
Cell dimensions     
    a, b, c (Å) 41.40, 60.62, 62.54 39.91, 51.17, 90.62 
    α, β, γ  (°)  90, 90, 90 90, 90, 90 
Resolution (Å) 41.38/1.00 (1.05/1.00)* 45.31/1.70 (1.79/1.70)* 
Rsym or Rmerge 0.098 (0.313)* 0.077 (0.159)* 
I / σI 17.8 (2.4)* 17.3 (9.3)* 
Completeness (%) 100 (95.32)* 99.7 (100)* 
Redundancy 6.3 (4.9)* 5.3 (5.4)* 
Refinement   
Resolution (Å) 41.38-1.00 90.54-1.70 
No. reflections 100817 112663 
Rwork / Rfree 0.17/ 0.18 0.18/ 0.21 
No. atoms 1616 1482 
    Protein 1387 1333 
    Ligand/ion 14 9 
    Water 215 140 
B-wilson 4.13 12.7 
  B-overall 6.29 10.6 
R.m.s deviations   
    Bond lengths (Å) 0.022 0.015 
    Bond angles (°) 1.958 1.406 
Table 1: Crystallographic data collection and refinement statistics for U43C and U43S SmGpx. 
*Highest resolution shell is shown in parenthesis.  
 
 
The structure of the U43C mutant evidences the presence of a few loops, one 
of which, connecting β1 to α1, hosts the catalytic cysteine (Cys43), which was here 
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found oxidized to sulphonic acid (Ocs43, SO3-) (Fig. 17A). The possibility that the 
oxidation of Cys43 could result in a local distortion of the active site structure, in 
order to accommodate the bulky sulphonic acid, seems unlikely, given that the 
superposition of the U43C SmGpx with the reduced U73C mutant of HsGpx4 does 
not show any macroscopic difference in the 3D structure of the two proteins (Fig. 
17B and section 4.2.3). However, to demonstrate this point, the U43S mutant was 
purified and crystallized as well. The crystal structure was solved by molecular 
replacement using the U43C SmGpx structure as the model (PDB code: 2v1m). Data 
were collected up to 1.7Å resolution and refined to the final Rfactor and Rfree values of 
18.2% and 21.2%, respectively (Tab. 1). The validation programs [84, 85] showed 
also for this second model a very good final geometry and density fit, with all 
residues lying in the preferred regions of the Ramachandran plot. The quantitative 
comparison of U43S with U43C SmGpx did not show any significant structural 
difference neither in the stereochemistry of the residues into the active site nor in the 
3D structure of the protein at large (RMSDmain chain=0.38 Å; RMSDside chain=1.21 Å). 
This finally leads to the conclusion that U43S SmGpx maintains the same 3D 
structure of the U43C mutant, strongly suggesting that the easier oxidation of Cys43 
does not perturb significantly the native structure of the enzyme. An additional proof 
in support of this statement came from the molecular dynamic (MD) simulations on 
SmGpx, where the in silico replacement of the SO3- group with functional Se- or 
SeOH groups did not determine any significant perturbation of the enzyme structure 
(see Chapter 3). 
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Fig. 17 Panel A: Ribbon representation showing the overall 3D structure of U43C SmGpx. Colour 
blending from N-terminus (blue) to C-terminus (red). The active site residues, including sulfonated 
catalytic Cys (OCS43), Gln 78, Trp 132, are shown as ball and stick and contoured with 2Fo-Fc electron 
density map at 1σ. Panel B: Superposition of U43C SmGpx (blue) and HsGpx4 (green). View of the two 
proteins from the top looking into the cleft surrounding the catalytic triad; residues different among the 
two are shown as ball and stick. 
 
 
4.2.3 Insight into the catalytic site of SmGpx 
The complexity of the Gpx superfamily, including different enzymes with 
various substrate specificity and cellular localization, does not result in a similar 
heterogeneity in the active site organization. It has been already demonstrated, for 
example, that bovine and human Gpxs display a highly similar pattern of catalytic 
residues, though classified as cytosolic (Gpx1) and extracellular (Gpx3) enzymes 
respectively. Two conserved amino acids, Gln and Trp, are crucial for the enzymatic 
activity of Gpxs, being localized at hydrogen bonding distance from the catalytic 
Sec; but recent results suggest that also the conserved Asn residue closer to Trp may 
play a role during catalysis [62, 64, 66]. 
SmGpx does not differ significantly from this pattern of active site residues: 
Q78, W132 and N133 are conserved in SmGpx (Fig. 15, 17A) and located at H-bond 
Chapter 4 
 
53 
distance from Ocs43 (Tab. 2), consistently with their presumed role in the 
stabilization of the reduced form of the native enzyme (R-Se-) during catalysis. 
 
SmGpx HsGpx4 
Atom 1 Atom 2 Distance Atom1 Atom2 Distance 
45 ALA/N 3.11 75 LYS/N 3.12 
46 THR/OG1 3.03 76 THR/OG1 3.03 
46 THR/N 3.04 76 THR/N 3.01 43OCS/O 
61 HOH 3.12 
 73CYS/O 
  
41 CYS/O 3.78 71 SER/O 3.79 
43OCS/N 46 THR/OG1 3.03  73CYS/N 76 THR/OG1 3.12 
44 GLY/N 3.39 75 LYS/N 3.48 
132 TRP/NE1 3.84 181 TRP/NE1 3.92 
43OCS/SG 
74 HOH 3.75 
 73CYS/SG 
164 ASN/ND2 3.63 
78 GLN/NE2 3.86    
132 TRP/NE1 3.49    
43OCS/OD1 
44 GLY/N 3.11    
132 TRP/NE1 3.08    
133 ASN/ND2 2.91    43OCS/OD2 
74 HOH 3.09    
44 GLY/N 3.22    
45 ALA/N 2.79    
46 THR/N 3.89    
43OCS/OD3 
74 HOH 3.27     
 Table 2: Inter residue contacts around the active Ocs43/ Cys73 in U43C and human HsGpx4 respectively. Distances 
shown are between each residue and the catalytic Ocs43/Cys73. Putative H-bonds (in bold) have been identified 
choosing a bond length cut-off of 3.10 Å [136] and allowing for an experimental error of 0.05 Å. Moreover, their bond 
angles have been checked and demonstrated to be compatible with the expected linear geometry. To describe how the 
angles were determined, we schematically represent the H-bond as X─D─H···A, where D is the donor atom and A is 
the acceptor. In our maps the H atom is not detected, thus the linear arrangement of atoms D─H···A cannot be checked 
directly. However, linearity can be safely assumed if the D─A distance is below the threshold and X─D─A angle is 
compatible with the known hybridization of D. 
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The structural superimposition of the U43C SmGpx with the U73C mutant of 
the HsGpx4 leads to an overall r.m.s.d of 0.68 Å. In particular the residues 
belonging to the SmGpx active site (C43, Q78, W132, N133) show an average 
displacement of 0.17 Å with respect the corresponding residues in the human 
enzyme. Hence the geometry of the active site is strictly conserved, the most 
obvious difference between the two enzymes being the redox state of the mutated 
catalytic cysteine, which is fully reduced in HsGpx4, while over-oxidated in SmGpx 
(Fig. 17B). 
All attempts to obtain a reduced U43C SmGpx, through different purification 
protocols employing several reducing agents, including TCEP, DTT, β-
Mercaptoethanol and GSH (see Chapter 3), were unsuccessful. The over-oxidated 
state of the catalytic C43 unfortunately compromised all the measurements of the 
enzymatic activity. Hence the enzyme was proved to be totally inactive, as well as 
the U43S mutant, at every stage of the purification and with the different substrates 
tested (see Chapter 3). The loss of activity was expected for the U43S mutant but not 
in the case of the U43C SmGpx, as the homologous HsGpx4 carrying the same point 
mutation and the same structural features was proved to be active [63]. 
The reason for the major tendency to auto-oxidation of the schistosome 
enzyme if compared with the human Gpx4 cannot be unequivocally assigned, but a 
more detailed comparison between the active site environments of the two enzymes 
gives some hints in this respect. Indeed superposition between SmGpx and HsGpx4 
with SSM methods (secondary-structure matching) shows a few point mutations 
involving residues surrounding the catalytic Cys: A45, K48, T153 and A154 in 
SmGpx are respectively mutated to K, V, E and E, in the human enzyme (Fig. 17B). 
A specific role for these residues is not immediately apparent, though the charge 
distribution around the catalytic Cys might be changed by the following 
substitutions: C41 of U43C SmGpx to S in HsGpx4 and A45 to K. The analysis of 
the surface charge distribution confirms that the active site pocket of U43C SmGpx 
has a strong positive charge, while in HsGpx4 the pocket is less positive and more 
hydrophobic (Fig. 18A-18B). Thus the most obvious difference between the human 
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and the schistosoma enzyme seems to lie in the greater polarity of U43C SmGpx 
active site, which could favour access to water and possibly metal ions that could 
exert a catalytic role and promote the oxidation of C43 to sulphonic acid. 
 
4.2.4 Static and dynamic clefts on SmGpx and their functional relevance 
With the aim to provide details about the catalytically relevant regions of 
SmGpx involved in the binding of specific substrates, such as glutathione 
(GSH/GSSG) and phospholipid hydroperoxides, the CASTp algorithm has been 
used to analyse the protein clefts (see Chapter 3). Two topologically equivalent 
cavities, close to the catalytic residue, have been identified in U43C SmGpx and in 
HsGpx4, having different areas and volumes: 140Å2/ 94Å3 for U43C SmGpx and 
93Å2/ 72Å3 for HsGpx4, respectively. A contribution to the greater extension of 
SmGpx pocket may be attributed to the lack of the H-bond between E158 and Q52, 
which in the human enzyme partially close the pocket shielding the catalytic C73 
from direct access to the solvent. 
The SmGpx cavity (yellow surface in Fig. 18C) is delimited by hydrophobic, 
polar and aromatic residues, which are close to the catalytic Ocs43 and in some 
cases form H-bonds with it (Tab. 2-3). Therefore, we refer to this cavity as the 
active-site cleft. CASTp also identifies a secondary crevice in SmGpx, centred on 
K131, having area and volume of about 107 Å2 and 57 Å3, respectively (magenta 
surface in Fig. 18C). This secondary cleft has limited access to C43, it is smaller 
than the active site one but has a greater density of positive charges (Fig. 18A and 
Tab. 3).  The two clefts are divided by a ridge that hosts C43, whose volume is 
increased because of oxidation and which seems to act as a flexible barrier in 
between. Elimination of sulphonic acid by mutation of C43 to S or by computational 
methods, does not change significantly this condition, except that the physical 
barrier between the two half-clefts is less prominent. 
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Figure 18 Panel A and Panel B: Representation of the electrostatic potential on SmGpx and HsGpx4, 
respectively. The higher density of positive charges surrounding the catalytic C43 in the parasite enzyme 
is evident. The two proteins are in the same orientation of SmGpx in panel C. In both proteins the position 
of the catalytic cysteine is pointed by an arrow. Electrostatic-potential maps were calculated with APBS 
[88], using the PDB2PQR server [89] and visualized with PyMOL [90]. Deep red corresponds to an 
electrostatic potential of -7 kT/e; deep blue corresponds to +7 kT/e. Panel C: Representation of the clefts 
detected by CASTp and MD analysis in SmGpx. Yellow: active site cleft; magenta: secondary cleft 
(putative GSH binding site). The catalytic Cys residue placed between the two clefts is shown as sticks. 
Panel D: Docking of phosphatidylcholine (PDB code CPL) on the active site cleft. The phosphorous atom 
is located in the negative pocket hosting a sulfate anion in the crystal structure, and the two fatty acid 
chains lie on top of the hydrophobic surface just above OCS43.  
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 CASTp on U43C 
crystal structure 
MD simulation on SmGpx 
Residues in the active site 
cleft 
OCS43 
Ala45 
Lys48 
Asn49 
Gln52 
Trp132 
 
Lys 136 
Pro151 
Thr152 
Thr153 
Ala154 
Pro155 
Sec43 
 
Lys48 
Asn49 
Gln52 
Trp132 
Phe134 
Lys136 
 
Thr152 
Thr153 
Ala154 
Pro155 
Tyr156 
Glu159 
Ile162 
Residues in the secondary 
cleft (putative GSH 
binding site) 
 
 
 
Ile130 
Lys131 
Trp132 
Ser135 
Arg148 
Gly124 
Thr125 
Asn129 
Ile130 
Lys131 
Trp132 
Ser135 
Arg148 
Tyr149 
Ser150 
Pro151 
Table 3: Residues lining the clefts identified by the static and dynamic analysis of 
SmGpx. The active site cleft is delimited by hydrophobic, polar and aromatic 
residues; the secondary cleft (smaller than the active site one) has a greater density 
of positive charges. Residues detected in both static and dynamic analysis are 
shown in bold. 
 
The results obtained from CASTp analysis are supported by the observations 
coming from MD simulations performed on SmGpx in different redox states (see 
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Chapter 3). During the simulations, transiently formed cavities with volumes 
ranging from 10 to a few hundreds Å3 are detected on the surface, close to residue 
C43. The volume distributions of such cavities, reported in Fig. 19A (upper panel) 
for reduced (Se-) and oxidized (SeOH) SmGpx, are by-and-large independent of the 
oxidation state of Sec. Dynamic analysis identified also a secondary positively 
charged cleft close to K131 which is detected for a fraction of time of 80-85% for 
both reduced and oxidized SmGpx (Fig. 19A bottom panel). In reduced SmGpx the 
volume distribution is characterized by a large single peak with a maximum at about 
200 Å3, while in oxidized SmGpx it is significantly broader and almost flat, with 
values ranging from 100 to 300 Å3. The motions of two loops, preceding and 
following helix α2 (β2a-α2 loop: residues 104-112, and the α2-β3 loop: residues 
122-134, Fig. 16), are specifically correlated to the fluctuations of the secondary 
cleft, as detected by essential dynamics (ED) analysis ([102] and Chapter 3), 
performed on the backbone of amino acids 104 to 140. In Fig. 19B the extreme 
configurations corresponding to the opposite values of the projection on the first 
eigenvector as determined from the simulations of   SmGpx(Se-) and SmGpx(SeOH) 
respectively, are reported. The approximate position of the cavity is highlighted by a 
sphere.The principal motions of the two loops, β2a-α2 and α2-β3, are correlated in 
both oxidation states. Therefore, MD simulation shows that in SmGpx(SeOH) the 
displacement of the β2a-α2 loop towards the active site is coupled with a 
displacement of the α2-β3 loop away from the β4 strand and thereby an increase of 
the cleft volume. On the other hand, in SmGpx(Se-) the coupling between the two 
loops is anti-correlated, since, when the β2a-α2 loop moves towards the active site, 
the distance between the α2-β3 loop and the β4 strand decreases and the cleft 
volume shrinks (Fig. 19B). The list of the main residues lining both the static and 
dynamic clefts (Tab. 3) shows that the core of both the active site and the secondary 
cleft detected by CASTp is superimposable to the pattern of residues lining the 
dynamic clefts. Therefore MD suggests that both clefts detected by CASTp may 
undergo transient expansion. This area/volume changes may be functionally 
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relevant, since the cleft’s volume from the static crystal structure appears too small 
to accommodate either substrate (i.e. the organic hydroperoxides or GSH). 
 
 A B  
 
 
 
 
Figure 19 Panel A: Relative frequency of the volume distributions of the active site cleft (upper 
panel) and of the secondary positively charged cleft (bottom panel), shown for the reduced (Se-, 
solid lines) and the oxidized (SeOH, dashed lines) states of SmGpx. Panel B: Extreme 
configurations from the most different eigenvalues for each simulation of reduced (Se-) and 
oxidized (SeOH) SmGpx. The directions of motion of the loops (β2a-α2 , α2-β3 preceding and 
following helix α2 are shown. The approximate position of the secondary cleft limited by the two 
loops is highlighted by a sphere. 
 
 
Although it is difficult to assign a specific functional role to each cleft 
identified in U43C SmGpx, mainly because the attempts to crystallize the enzyme in 
the presence of its substrates did not gave any positive result, the information 
coming from the crystal structure here presented and from the surface analysis 
allowed to hypothesize a binding region for both phospholipid hydroperoxides and 
GSH/GSSG on SmGpx. 
Functional studies have proved that class 4 Gpxs prefer phospholipid 
hydroperoxides as substrates over-and-above H2O2 or other organic hydroperoxides 
[50]. Moreover it is known that schistosomes, being unable to synthesize de novo 
fatty acids, upload these compounds from the host and that adult worms usually use 
the host oleate (18:1) and elongate the chain to eicosenoate (20:1), which is 
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incorporated predominantly in the phosphatidylcholine molecule together with 
palmitate (16:0) [113]. An automated docking procedure (see Chapter 3, [91]) has 
been here employed in the attempt to identify a possible binding site for 
phosphatidylcholine (PC) in U43C SmGpx in the proximity of C43 (Fig. 18D). In 
spite of the high flexibility of the substrate PC, under the assumption that the 
phosphate (P) of PC occupies the same site of the sulphate or pyrophosphate anion 
present in U43C SmGpx and U43S SmGpx respectively, a plausible PC binding site 
was identified, comprising: (i) the residues surrounding the active site cysteine (43-
45 and 74-77) (the Cys residue should act on the peroxidatic double bond of the 
phosphatidylcholine hydroperoxide fatty acid chains) and (ii) those surrounding the 
strongly positive pocket (57Å3) next to the catalytic Cys hosting a 
sulfate/pyrophosphate anion (residues 123-133 and 148-151). MD simulations had 
already shown that such a pocket undergoes relevant expansions in solution, 
enabling it to accommodate larger substrates (Fig. 19A). The program Patchdock 
optimized the position of the substrate, with the following constraint: P to R148 
distance=3.9 Å. Although this procedure is somewhat arbitrary, it is useful to 
suggest a possible orientation of a highly flexible substrate. It is possible that when 
the phosphate group of the phosphatidylcholine is located in the pocket containing 
the sulfate or pyrophosphate anion, the two fatty acid hydrophobic chains may lodge 
on top of a large hydrophobic surface located above the catalytic cysteine, 
positioning C43 close to C9-C10 double bond of the eicosenoic acid. This 
observation may have a functional relevance as it is known that over-oxidation of 
unsaturated fatty acids occurs usually on a double bond located around C10 yielding 
similar oxidation products for monoene-, diene- and triene- fatty acids [114] (Fig. 
20). With respect to the GSH binding site on Gpx enzymes, the unique information 
available in literature comes from the work of Epp et al., who proposed a model 
based on differences in the electron density maps between the oxidized and GSH 
reduced wild type bovine cellular enzyme (PDB code: 1GP1, [62]). They concluded 
that three residues (R57, R184 and M147) are involved in GSH binding. Sequence 
alignment and structural superposition allowed us to trace the equivalent positions in 
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U43C SmGpx. This putative GSH binding site overlaps with the secondary cleft in 
the schistosoma enzyme, even though the residues that should interact with GSH are 
different. In fact, while the putative role of R57 could be played in U43C SmGpx by 
K48, R184 is mutated to P150 and an equivalent of M147 is absent. The latter 
observation is consistent with the fact that SmGpx is a monomeric enzyme, while 
bovine Gpx1 is tetrameric: in the bovine enzyme M147 is localized in a loop of 
residues involved in the dimerization of oligomeric Gpxs which is absent in the 
monomeric enzymes, such as SmGpx (Fig. 15). In view of these differences, the 
hypothesis that the functional role of the secondary cleft is to provide the actual 
GSH binding site must be considered with caution, though the high concentration of 
positive charges in this cleft together with its dynamic volume fluctuations, 
occurring when the enzyme passes through the two redox state of its catalytic cycle 
(from R-Se- to R-Se-OH), makes it plausible. 
 
 
 
 
 
 
Fig. 20: Main steps of membrane lipid peroxidation: (A) initiation of the peroxidation process by an 
oxidizing radical X·, by abstraction of a hydrogen atom; (B) oxygenation to form a peroxyl radical and a 
conjugated diene; (C) peroxyl radical moiety partitions to the water-membrane interface; (D) peroxyl 
radical is converted to a lipid hydroperoxide; (E) the enzymes phospholipase A2 (PLA2), glutathione 
peroxidase 4 (GPX4), glutathione peroxidase (GPx) and fatty acyl-coenzyme A (FA-CoA) cooperate to 
detoxify and repair the oxidized fatty acid chain of the phospholipid (adapted from [115]). 
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II part: Thioredoxin Glutathione Reductase from S. mansoni (SmTGR) 
 
4.3 Expression and purification of two mutants of SmTGR 
The gene coding for a GST-fused SmTGR, lacking the last two amino acids 
Sec597-Gly598, cloned into a pGEX-4T1 vector, was expressed in BL21(DE3) E. 
coli cells upon induction with IPTG, in order to obtain the truncated form of the 
enzyme (SmTGRtr) (see Mat. & Met.). The gene coding for SmTGRtr was used as a 
template to synthesize the U597C mutant gene for full-lenght TGR (see Chapter 3). 
The expression of this construct in BL21(DE3) E. coli cells without IPTG induction 
gave the best results in terms of protein yield. For both mutants the SDS-PAGE 
analysis confirmed the presence of a band at about 90 kDa corresponding to the 
molecular weight of the GST fused with a monomer of SmTGR. The protein purity 
was >98%, after the thrombin cleavage and removal of the GST tag by affinity 
chromatography. 
The two SmTGR mutants showed the typical UV-VIS spectrum of 
flavoenzymes having an absorption peak at 280 (due to both the protein and its FAD 
cofactor) and another peak at 460 nm (representative of the FAD) which has been 
used to estimate the protein concentration (see Chapter 3 and Fig. 21).  
 
 
 
 
Fig. 21: absorption spectra of SmTGRtr in different redox states. Spectrum 1: 15 µM of oxidized SmTGR 
(ε460 = 11,300 M-1 cm-1). Spectrum 2: SmTGR reduced with 4 equivalents of NADPH (ε340 = 6220 M-1 
cm-1), 1 min after the addition of reductant. Spectrum 3: SmTGR reoxidized by 1 mM GSSG, 1 min after 
the addition of oxidant. 
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Both the truncated and U597C SmTGR have been employed in crystallization 
experiments and their structures have been solved (PDB codes: 2V6O, 2X8C, 
2X8G, 2X8H, 2X99). However, given the absence of relevant structural changes 
between the SmTGRtr and the oxidized form of U597C SmTGR, the former will be 
excluded from the structural description reported below.  
 
4.4 Structural characterization of intermediates of the catalytic cycle of 
SmTGR  
As described in section 1.6, SmTGR is a homodimeric flavoprotein belonging 
to the class of the pyridine nucleotide oxidoreductases, which includes also 
thioredoxin reductase (TR) and glutathione reductase (GR) [48]. The structural 
characterization here presented explains how the peculiar domain organization of the 
parasite's SmTGR  makes it able to exploit the functions which normally compete to 
both TR and GR in the mammalian hosts, being involved in the transfer of reducing 
equivalents from NADPH to both the GSH and Trx antioxidant systems, in order to 
finally permit the reduction/detoxification of hydrogen peroxide and organic 
peroxides to H2O2 and hydroxides respectively. The active cysteine couples located 
in different domains of the protein (i.e.: the C-terminal Gly-Cys-Sec-Gly 
tetrapeptide, the FAD binding site, and the N-terminal glutaredoxin domain) are at 
the base of the reducing activity of SmTGR (Fig. 22). 
Several structures of TR and GR from different organisms have been solved 
[44, 116-118], but the absence of details about the 3D organization of TGRs has 
prevent the elucidation of its catalytic mechanism. Furthermore the demonstration 
that TGRs from different parasites (Schistosoma among them) are targets of choice 
for the development of new drugs, because of their key role in the life-maintenance 
of the parasites inside the human host, has made more and more interesting the 
elucidation of the macromolecular organization and of the mechanism of action of 
such enzymes [29, 71, 119]. 
In this respect the following sections will provide a detailed description of 
TGR from Schistosoma mansoni, with insight into the main structural changes 
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which accompany the redox transformations occurring during the catalytic cycle. 
The U597C mutant of SmTGR has been crystallized in different redox states: (i) a 
fully oxidized form [Structure 1 (1.9 Å)]; (ii) a partially reduced form, obtained 
either in the presence of NADPH and reduced glutathione (GSH) [Structure 2 (2.3 
Å)] or (iii) with GSH alone [Structure 4 (1.9 Å)]; (iii) and a species having the fully 
reduced C-terminal tetrapeptide [Structure 3 (3.1 Å)], whose relevance for the 
catalysis will be further explained below. The statistics of the diffraction and 
refinement data for each of the four structures are summarized in Tab. 4. 
 Structure 1 Structure 2 Structure 3 Structure 4 
Data collection 
Space group  C2 C2 P212121 C2 
Cell dimensions       
 a, b, c (Å) 141.6 102.8, 59.2 141.6, 102.6, 60.0 84.5, 87.4, 185.5 141.6, 102.9, 59.1 
    α, β, γ  (°)  90, 112.4, 90 90, 112.8, 90 90, 90, 90 90, 112.6, 90 
Resolution (Å) 40.0/1.9 (2.0/1.9)* 40.0/ 2.3  (2.4/ 2.3)* 30.00/ 3.1 (3.2/3.1)* 40.0/ 1.9 (2.0/ 1.9)* 
Rmerge 0.1 (0.3)* 0.1 (0.4)* 0.1 (0.5)* 0.1 (0.4)* 
I / σI 12.2 (3.2)* 18.4 (3.8)* 11.8 (2.6)* 9.6 (5.4)* 
Completeness (%) 90.1 (92.6)* 100 (99.9)* 99.3 (99.2)* 100 (99.7)* 
Redundancy 3.0 (2.8)* 8.1 (7.8)* 7.1 (7.0)* 5.7 (5.7)* 
Refinement     
Resolution (Å) 40.0/1.9 40.0/ 2.3 30.0/ 3.1 40.0/ 1.9 
No. reflections 52,728 33,294 24,221 58,385 
Rwork / Rfree 0.19/0.21 0.19/ 0.23 0.22/ 0.29 0.18/ 0.19 
No. atoms 4863 4936 9174 5008 
Protein 4502 4502 9031 4504 
Ligand/ion 106 249 143 139 
Water 255 185 0 365 
B-wilson 19.0 35.1 63.4 14.6 
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 Structure 1 Structure 2 Structure 3 Structure 4 
   B factors      
Overall 18.6 22.5 43.5 14.6 
Main chain 17.6 20.1 43.3 13.0 
Side chains 19.6 24.7 43.7 16.1 
R.m.s deviations     
Bond lengths (Å) 0.008 0.011 0.009 0.007 
Bond angles (°) 1.064 1.302 1.164 0.978 
Model quality     
Ramachandran plot     
Most favoured 91.4% 91% 86.3 92.6 
Additional allowed 8.4% 9.0% 13.5 7.2 
Generously allowed 0.2% 0% 0.3 0.2 
Table 4: Crystallographic data collection and refinement statistics (* Values in parentheses refer to the highest resolution shell) 
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Fig. 22: Electron transfer in and out of the TR domain of SmTGR. When NADPH binds to the oxidized 
state of the enzyme (Structure 1), electrons are transferred from the nicotinamide ring to the FAD; reduced 
FADH2 shuttles electrons to Cys154-Cys159 couple (in red) close to the isoalloxazine ring of FAD (as 
observed in Structure 2), and finally electrons reach the Cys596-Sec597 redox couple on the C-terminal 
segment of the other subunit (in blue, as observed in Structure 3). The C-terminus acts as a flexible arm, 
which might donate electrons either internally to the Cys28-Cys31 active couple on the oxidized Grx 
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domain (in green) or externally to various oxidized substrates such as SmTrx (in dark grey). SmTGR 
redox species populated during the catalytic cycle are shown, from the fully oxidized enzyme (Eox) to the 
two-electrons reduced forms (EH2A, EH2B, EH2C), to the final four-electrons reduced species (EH4A, 
EH4B). 
  
4.4.1 The oxidized form of SmTGR (Structure 1) 
Overall structure: fusion of thioredoxin reductase (TR) and glutaredoxin 
(Grx) domains 
In order to obtain the fully oxidized enzyme, crystals of the U597C mutant of 
SmTGR were incubated for 48h with a 2mM solution of copper sulphate (see 
Math&Meth). The resulting oxidized SmTGR represents the first step of the 
catalytic cycle and is able to accept reducing equivalents from the NADPH donor 
(Structure 1, Fig. 22). The structure was solved at 1.9 Å resolution and the map gave 
the possibility to fit residues from 6 to 593. The refined model consists of one 
monomer per asymmetric unit. Since the enzyme in solution is a dimer as 
demonstrated by high resolution gel-permeation (HPLC, result not shown), the 
crystallographic dimer generated by reflection on the twofold symmetry axis is the 
biological unit (Fig. 23A-23B). 
The overall structure of the enzyme reveals that each monomer results from 
the unusual fusion of two domains: a smaller Grx domain, ranging from residues 1 
to 106 (green in Fig. 23), and a larger TR domain, including residues 107–598 (red 
and blue in Fig. 23). The Grx domain shows a typical thioredoxin/glutaredoxin fold. 
The secondary structure of this region, in fact, comprises a central four-stranded β-
sheet (the first two β-strands are parallel and the other two are antiparallel) and five 
surrounding α-helices (Fig. 24). The same fold has been already detected in several 
isoforms of Grx from eukaryotes, having either a monomeric or dimeric 
arrangement (PDBcodes: 1Z7R [120], 2HT9, 3C1R [121], 3CTF, 3L4N [122]). The 
loop comprising residues 103-108 connects the Grx domain of SmTGR, located at 
the N-terminal portion of the protein, to the large TR domain. The overall fold of the 
TR domain is typical of a member of the pyridine nucleotide-disulphide 
oxidoreductase family, thus very similar to the general folding of TR and GR 
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enzymes. As already discussed for the 3D organization of mammalian TR and GR 
[117, 118], enzymes belonging to the above-mentioned family usually assemble as 
functional homodimers, and in each monomer three sub-domains can be recognized: 
(a) an N-terminal FAD binding domain, (b) a central domain for NADPH-binding, 
and (c) a C-terminal interface domain. A superposition between rat TR (rTR, 
PDBcode: 1H6V, [117]) and the oxidized form of SmTGR (Structure 1) allowed the 
identification in the TR portion of the worm enzyme of the corresponding sub-
domains, comprised between the following residue ranges: (a) 105-259 and 397-466 
(red in Fig. 25), (b) 260-396 (yellow in Fig. 25) (c) 467-593 (cyan in Fig. 25). The 
first two sub-domains are variants of a Rossmann fold, being composed of a larger 
five-stranded parallel β-sheet flanked by a smaller three-stranded β-sheet on the one 
side and a different number of α-helices on the other side (Fig. 25-26). The 
secondary structure of the third sub-domain shows a central five-stranded 
antiparallel β-sheet, with four flanking α-helices (Fig. 25-26). The binding site of 
NADPH and its interaction with the residues surrounding the FAD cleft will be 
discussed in section 4.4.2, while the monomer-monomer interface will be described 
in details below. 
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Fig. 23 Panel A: Structure 1, SmTGR in its oxidized state. Green: Grx domains; Blue and red: TR 
domains. The FAD cofactors, one for each monomer, are bound in close proximity of the C-terminal 
segment of the protein and are shown as spheres. Two redox centers of SmTGR are shown, with the 
sulphur groups of the reactive cysteine couples (C28-31, C154-159) represented as orange sticks. The 
third reactive cys couple (C596-C597) is not visible in the electron density map, but the position of the C-
terminal arm of monomer A is pointed by an arrow. Panel B: same structure as in panel A but the view is 
from the top, looking down the twofold dimerization axis, shown in black. 
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Fig. 24: Sequence alignment between the Grx domain of SmTGR (residues 1-104) and Grx proteins from 
different organisms: Homo sapiens (Hs), Mus musculus (Mm), and Rattus norvegicus (Rn). The alignment 
files obtained with ClustalW have been visualized with ESPript. The secondary structure of the Grx 
domain of SmTGR is shown in the top line. Identical residues are boxed in red, similar residues in red, 
non-conserved residues in black. 
 
 
 
 
 
 
Fig. 25: Localization of the three sub-domains comprised in one monomer (A) of SmTGR. Red: FAD 
binding domain; yellow: NADPH-binding  domain; cyan: interface domain. The adjacent monomer of 
SmTGR is shown in light grey. The position of the C-terminal segment of monomer A (close to the FAD 
binding site of monomer B) is pointed with an arrow. 
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Fig. 26: Sequence alignment between SmTGR and TGR, TR and GR from different organisms. Hs= 
Homo sapiens; Mm= Mus musculus; Rn= Rattus norvegicus. The alignment files obtained with ClustalW 
have been visualized with ESPript. The secondary structure of SmTGR is shown in the top line. Identical 
residues are boxed in red, similar residues in red, non-conserved residues in black. 
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 A structural superposition between a monomer of U597C oxidized SmTGR 
and those of both human GR (hGR, PDBcode: 3DJG) and the U498C mutant of 
human TR (hTR, PDBcode: 2ZZ0) shows that some structural features make 
SmTGR more similar to TRs than to GRs (Fig. 27). In common with TR, SmTGR 
presents 16 extra residues (carrying the Gly-Cys-Sec-Gly consensus sequence) at the 
C-terminus, which is absent in GR. Moreover two insertions in the schistosoma 
enzyme (residues 139–149, and residues 238–245) can be exactly superimposed to 
analogue sequences in hTR but do not have an equivalent portion in hGR (Fig. 27). 
The same features are evident from a superposition of SmTGR with rTR (1H6V) 
(results not shown). The two loops resulting form these insertions seem to shield the 
adenine of the FAD, which is more buried in TGR and TR if compared with GR 
enzymes [117]. A unique feature in the structure of SmTGR, absent in other 
members of the GR family, is an extended and solvent accessible mobile loop 
(residues 359–364), constituted by a group of polar residues (D-T-E-N-N-K), 
positioned at the bottom of the structure under the FAD binding site. This loop lies 
below two β-strands (residues 347-356 and 367-375) belonging to the NADPH 
binding domain (Fig. 27). 
 
 A B  
 
 
 
 
 
Fig. 27: Superposition of the 3D structure of monomer B of oxidized SmTGR with either one monomer of 
hTR (Panel A) or hGR (Panel B). Green: SmTGR; orange: hGR; cyan: hTR. In black are shown the  
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regions of the worm enzyme which makes it more similar to TR than to GR enzymes. 
 
The dimer interface 
Dimerization in SmTGR occurs through the larger TR domains and results in a 
distorted ‘‘W’’ structure, with the two Grx domains positioned at the top of each 
outer arm of the W (Fig. 23A). The monomer–monomer contact area is composed of 
an antiparallel five stranded β-sheet, flanked on each side by two α-helices 
(α16−α17 on one side and α18-α19 on the opposite side) and a 310 helix (η6 on one 
side and η7 on the other). For the sake of clarity the nomenclature of the secondary 
structure elements is the same shown in the sequence alignment in Fig 26. 
The total surface area buried in the dimer interface (4120 Å2) is mostly due to 
complementarity of residues within the helices α18 of both monomers, with a 
central role played by a network of Van der Waals interactions, mainly involving 
residues G550, Y551, V553, A554 and I555 from each monomer. A series of 
symmetric polar contacts participate also to the dimerization of the protein, and 
engage the following couples of residues: E546-S575/N (2.9 Å), Q549-E576/N (3.6 
Å), Q549-I570/N (2.8 Å), where the former residue belongs to one monomer and the 
latter comes from the adjacent monomer. Moreover E509 forms also a polar contact 
with K163 of the FAD binding domain of the adjacent monomer (2.9 Å). Most of 
these residues are conserved in TRs (Fig. 26). 
Just at the bottom of the interface region carrying the above residue couples, 
there is an additional contact area between the monomers that worth to be 
mentioned, because it has been demonstrated to be involved in the binding of 
noncompetitive inhibitors in hGR (PDB code: 1XAN, [123]). It is a large cavity, 
leaned by couples of hydrophobic residues coming from both monomers (F78, V74, 
L438, W70, Y407 in hGR). This cavity is present also in SmTGR, but it is coated by 
more polar residues (A174, L170, P542, H166, E509) and these residues are highly 
conserved between SmTGR and hTR. Thus it can be summed up that the sequence 
identity of the dimer-dimer interface of SmTGR is higher with TR than with GR, 
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even if the interface region is similar among the three enzymes, given that the largest 
contact area is due to α18 helices from each monomer. 
The FAD binding site 
Each TR domain of SmTGR contains a large cleft which hosts the FAD 
cofactor. The two symmetric FAD binding sites are both located at the interface and 
each noncovalently bound cofactor interacts with residues from both TR domains 
(Fig. 23A-28), as typical of TRs and GRs [117, 118]. Like in other FAD-disulfide 
oxidoreductases, the FAD is bound in an extended conformation and most of the 
neighboring residues are conserved in the GR superfamily. The adenine is bound in 
a polar pocket closed on the top by a salt link between K399 and E140 (NZ/K399-
OE1/E140 = 2.7 Å). The isoalloxazine ring is sandwiched between Y296 (on-face 
OH-N10 distance of 3.4 Å) and the couple C154-C159 (C159 SG-N1 distance of 3.2 
Å), which is oxidized in this structure (Fig. 28). Y296 and the Cys couple are 
invariant in GR and TR enzymes (Fig. 26). 
 
 
 
 
 
Fig. 28: FAD binding site in the oxidized SmTGR. The FAD cofactor bound to monomer A (red) is here 
shown. The surrounding residues mainly involved in the formation of H-bonds with the cofactor are 
shown in sticks. The pink ball represents the water molecule which mediates the contact between O2 of 
the flavin and the peptidyl N of H571/A. 
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The FAD ring is firmly kept in place by a network of H-bonds, with residues 
coming from both monomers. In particular, O4 of FAD/A is at 2.8 Å distance from 
NZ of K162/A, on the same side of the S-S bridge formed by C154-C159/A. N3 is at 
2.7 Å from the mainchain O of H571 of the other monomer (B), and O2 contacts the 
peptidyl N of H571/B via a water molecule (O2-HOH71 = 2.6 Å; HOH71-N/H571 = 
3.0 Å); O2 is also at H-bond distance (3.0 Å) from N of T442/A (Fig. 28). This 
architecture leaves atoms N1 and N5 of the FAD cofactor free to react respectively 
with C159, on one side, and the nicotinamide ring on the other, the latter only after 
displacement of Y296 (see section 4.4.2). Furthermore, the side chain of H571/B is 
oriented between the carboxyl group of E576 of the same monomer and the S-S 
bridge of the adjacent monomer (Fig. 28). H571 may be important for the S-S bridge 
reactivity, because its stereochemistry and the spherical shape of its electron density 
suggest a torsion movement, which could bring ND1 alternatively toward E576 and 
C154. 
The redox centers 
The enzymatic activity of SmTGR, aimed to transfer reducing equivalents 
form NADPH through the enzyme and then to the SmTGR oxidized substrates, 
basically involves a series of disulphide exchange reactions. Thus the cysteine 
residues of the protein play a crucial role in the catalysis. SmTGR contains 15 Cys 
per monomer, three of them located in the Grx domain and 12 in the TR one, 
including the C-terminal Sec597, which is mutated in Cys in the enzyme here 
described. At least six of these Cys are conserved in couples and are known to 
change their oxidation state during the catalytic cycle: (i) C154 and C159 located 
directly on top of the FAD cofactor (Fig. 23A-28); (ii) C596 and Sec597 at the C-
terminal end of the polipeptidic chain; (iii) C28 and C31 placed in the Grx domain 
(Fig. 23A). In this structure of the U597C mutant the redox couple C28-C32 of the 
Grx domain and the C154-C159 couple of the TR domain are both fully oxidized, 
the distances between the two sulphurs being 2.1 Å in both cases. The position of 
Y296 is also consistent with this state, the aromatic ring being perpendicular with 
the isoalloxazine ring of FAD. 
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4.4.2 The complex SmTGR-NADPH (Structure 2) 
With the aim to determine the structural changes associated with the binding 
of NADPH to SmTGR in the first step of the catalytic cycle, when a NADPH 
molecule transfers reducing equivalents to the oxidized enzyme, the U597C mutant 
of SmTGR has been crystallized in the presence of NADPH. The structure of the 
complex has been determined at 2.3 Å resolution (Structure 2, Fig. 22). Because of 
the presence of reduced glutathione (GSH) in the crystallization buffer also this 
reductant could be detected in the electron density maps, hence the whole refined 
model consists of one monomer per asymmetric unit, plus one FAD, one NADPH 
and two GSH molecules. 
By and large Structure 2 differs from Structure 1 mainly for the oxidation state 
of the redox site onto the Grx domain and for slight side chain movements of some 
residues in the FAD and NADPH binding pockets. The C28-C31 couple in fact is 
here reduced, probably as a consequence of an excess of GSH present in the 
crystallization buffer; while C154 and C159, the two active residues on the si-face of 
the isoalloxazine ring of FAD, are found in both redox states. In this respect Cys154 
appears in a double conformation (each with 0.5 occupancy), while C159 maintains 
the same position shown in Structure 1. Thus the distance between the two sulphur 
groups is 3.1 Å in the reduced state and 2.1 Å in the oxidized one. Moreover, C159 
is at 3.2 Å from C4 and C10 of the isoalloxazine ring of FAD and might be 
implicated in a charge transfer complex, as already observed in human GR (pdb 
code: 3djg, [118]). The reduced C154 forms a H-bond with a water molecule (2.7 
Å), kept in place by H571 of the adjacent monomer (Fig. 29A). H571 might have a 
role in the stabilization of the FAD-thiolate charge transfer complex, as it has been 
already hypothesized for the corresponding Hys residue in TR from Drosophila 
melanogaster crystallized in the presence of excess NADPH [124]. 
The NADPH binding site is mainly composed by three loops involving 
residues 292-297, 317-324, and 391-393. NADPH binds on the re-face of FAD (si-
face and re-face of FAD are assigned following the rules of Hanson K.R. [125]), and 
is stabilized by the following electrostatic interactions: a cation-π bond between 
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R317 and the adenine; a salt bridge between R322 and the phosphate on ribose C2; 
and two H-bonds between S295-NADPH(AO2) and S318- NADPH(AOP2). The 
nicotinamide ring of NADPH is sandwiched between the isoalloxazine ring of FAD 
(at a distance of 3.8 Å) and the aromatic ring of Y296 (3.6 Å) (Fig. 29A). Y296 
swings upon NADPH binding, and is stabilized in this new position by hydrophobic 
contacts between the phenol ring and the side chains of P324 and V473 (as also 
reported for human TR, [117]). 
GSH has been detected in two distinct sites of the structure. The first one lies 
in the Grx domain and will be described below  in Structure 4 (see section 4.4.4). 
The second GSH is found in the TR domain, in a pocket formed by one α-helix 
(L397-T404), a β-strand (K227-L230) and the nucleotide moiety of the FAD. The 
Cys of GSH is engaged in a disulfide bond with C402 (2.1 Å). The rest of the 
molecule is stabilized by polar contacts with K227, G228, R229 and L230. 
Moreover the carboxylate group of the γ-glutaminyl end is at 2.9 Å from FAD 
adenine amine group (Fig. 29B). The binding of one GSH molecule in the TR 
domain is accompanied by a change in the conformation of the region in between 
residues 397-404, if compared to the unliganded structure (PDB code: 2v6o, [75]) 
(Fig. 29B). The presence of GSH forces the loop 397-404 to turn around two pivot 
residues (L397 and T404) and to acquire a 2-turn α-helix structure. As a result, the 
hydrophobic side chains of V400 and L401 are exposed to the solvent and GSH 
takes the place previously occupied by the loop (Fig. 29B). The presence of 
NADPH/NADP+ in its binding site might be somehow correlated with the 
glutathionylation of C402, given that (i) attempts to co-crystallize the enzyme with 
NADPH in the absence of GSH were always unsuccessful; (ii) the change in 
conformation of the above mentioned loop is close to the gate of the NADPH 
binding site (Fig. 29B). At the moment we are unable to propose a rationale to the 
concomitant presence of the two ligands, especially in view of the fact that C402 is 
not a member of a redox cys couple. 
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Fig. 29: NADPH and GSH binding sites in Structure 2. Panel A. Zoom in the FAD active site. The 
NADPH and FAD are shown in green sticks, Y296, S295, C154, C159 in red sticks, while H571 of the 
partner subunit is shown in blue sticks. Upon NADPH binding, the loop 292-297 changes conformation 
re-orienting the side chains of S295 and Y296 with respect to Structure 1 in order to make room for the 
reductant. The C159-C154 couple is partially reduced and accordingly C154 is found in a double 
conformation. In the reduced conformation (50% occupancy) the sulphur of C154 points towards the 
solvent and is in contact with a water molecule (2.7 Å, shown as red ball), which is kept in place by H571. 
Panel B. The GSH binding site on TR domain of Structure 2. The GSH (in green sticks) is found in a 
position that in other TGR structures is usually occupied by the loop 397-404 (in cyan ribbon). The ligand 
is found in a pocket formed by one α-helix (L397-T404), a β-strand (K227-L230) and the nucleotide 
moiety of the FAD. GSH makes a mixed disulphide with C402 and forces the loop 397-404 to adopt a α-
helical secondary structure (in red ribbon) by turning around two pivot residues L397 and T404 (shown as 
full black circles). One of the gates of the NADPH binding site (black square) is four residues upstream of 
L397. 
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4.4.3 The C-terminal reduced form of SmTGR (Structure 3) 
The structure of the U597C mutant of SmTGR showing its C-terminal 
segment in the fully reduced state (Structure 3), solved at 3.1 Å resolution, is unique 
among the four structures here reported in that it presents a P212121 space group. The 
main differences between this structure and the others reported so far (pdb codes: 
2v6o, 3h4k, Structure 1, and Structure 2) are the presence of the physiological dimer 
in the asymmetric unit and the structuring of the C-terminal arm, whose density is 
visible in one of the two monomers. 
The low resolution did not permit an accurate estimate of the redox state of the 
cysteine couple at the FAD  active site (C154-C159) and at the Grx redox site (C28-
C31), because (i) the slight configurational change of C154 with respect to C159 
upon reduction (~ 1.0 Å. see Structure 2) would be hard to detect , also in view of 
the fact that the electron pair is shared between the FAD and the C154-C159 couple, 
leading to the latter being only partially reduced, as in Structure 2 (consistent with 
the rapid kinetic experiments, see section 4.5.2); and (ii) both the Grx domains are 
characterized by high mobility indicated by the high B factors. In fact too weak 
electron density did not permit the assignment of the first five residues at the N-
terminus of both monomers, as well as of the last five residues at the C-terminal 
portion of monomer A. On the contrary a stronger electron density allowed the 
building of the entire C-terminal segment of monomer B, implying a structural 
asymmetry in the organization of the two monomers. A second evidence of this 
asymmetry comes from the different thermal factors of the two Grx domains 
(residues 7-104): the Grx portion of monomer A being rather less mobile (overall 
<B> = 57.0 Å2) than the Grx domain of monomer B (overall <B> = 88.6 Å2). 
The terminal tetrapeptide G-C-C-G, as it appears in the electron density map, 
is fully reduced, the two cysteine residues (C596-C597) being in a trans position 
with respect to the main chain and pointing their sulphur atoms toward the solvent 
(Fig. 30). The positioning of the C-terminus is permitted by a kink centered on 
residue K586. This conformation is stabilized by several H-bonds and salt bridges 
(listed in Tab. 5), mostly with residues of the B monomer. Hence the C-terminus of 
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the B monomer lies in the central cavity of SmTGR W-shaped homodimer, with the 
terminal tetrapeptide, containing the catalytic cysteines, located at only 13 Å from 
the C154-C159 redox couple of the FAD catalytic site of monomer A, a distance 
compatible with the reducing activity of the C-terminus (Fig. 30). 
 
4.4.4 The complex SmTGR-GSH (Structure 4) 
In the absence of NADPH, only one molecule of GSH per monomer was 
found in the electron density map. It is located at the redox site on the Grx domain, 
as already quoted for Structure 2. The 3D structure of U597C SmTGR in complex 
with GSH was determined at 1.9 Å resolution (Structure 4), the refined model 
consisting of one monomer per asymmetric unit, with residues ranging from 6 to 
593, as in the previous structures here presented. 
Electron density of the GSH molecule was detected in the proximity of C28, 
the redox active site of the Grx domain (Fig. 31). The distance between the sulphur 
atoms of C31 and C28 is 3.2 Å, suggesting that these Cys are reduced, as expected, 
given the high GSH concentration present in the crystallization conditions. As 
observed in Structure 2 the C154-159 couple is partially reduced, probably as a 
result of the reversible electron transfer between FADH2 and the close cys couple. 
The average B-factor of the GSH ligand is slightly higher (by ~5 Å2) than that of its 
surrounding residues. The GSH is kept in place by the following H-bonds 
established with the surrounding residues: (i) S85 binds the γ-glutamyl moiety 
(OG/S85-O12/GSH = 2.5 Å; N/S85- O11/GSH = 2.9 Å); (ii) V72 forms two H-
bonds with the central region of GSH (O/V72-N2GSH = 3.0 Å; N/V72-O2/GSH = 
2.8 Å) orienting the sulphur atom towards the redox active site of the Grx domain 
(3.4 Å is the distance between the sulphur of GSH and the sulphur of C28); and (iii) 
Q60 and K25 bind the glycine moiety of the ligand (NZ/K25-O32/GSH = 2.8 Å; 
NE2/Q60-O31/GSH = 2.9 Å) (Fig. 31). 
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Fig. 30: Ribbon representation of the C-terminal region of monomer B in Structure 3. The two catalytic 
Cys belonging to the C-terminal arm (C596, C597), shown in blue sticks, are both reduced; C597 is 
located about 13 Å from C154-C159 couple (see text). The positively charged residues K124, K128 and 
R450 of the adjacent monomer involved in the stabilization of the C-terminal arm are shown in red sticks. 
 
 
 
 C-terminal residue 
(monomer B) 
Residues from monomer A Residues from monomer B Distance (Å) 
V583(O)  H502(N) 3.0 
T584(OG)  S587(OG) 2.9 
K585(N)  V500(O) 2.9 
K585(O)  G588(N) 2.8 
K585(NZ)  E327(OE1) 2.8 
K585(NZ)  Q327(OE1) 2.8 
P591(N)  N504(O) 3.3 
V593(N)  N518(OD1) 2.7 
G598(O) K124(NZ)  2.4 
 
 
 Table 5: Polar contacts between the C-terminal arm and the TR domain of SmTGR accordingly to Structure 3.  
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Fig. 31: The GSH binding site on the Grx domain in Structure 2 and 4. GSH (in cyan sticks) is in a pocket 
above the redox site of the Grx domain (C28-C31, in green sticks). Residue surrounding the ligand are 
shown in stick and polar contacts are represented by dotted lines. The GSH sulphur points towards C28 
and its position is stabilized by contacts with V72. The carboxylate of the glutamic acid of GSH is H-
bonded to Q60 and K25. 
 
 
4.5 Functional studies on SmTGR 
With the aim to assess the ability of the U597C SmTGR mutant used in our 
crystallographic studies to reduce its physiological substrates, a functional 
characterization of the enzyme has been carried out. Both stopped-flow and 
spectrophotometric experiments are described in the following sections. A 
comparison with the activities of the truncated SmTGR, lacking the C-terminal 
tetrapeptide (SmTGRtr), and those of the wild-type SeCys-containing enzyme 
(SmTGRwt) are also presented, in order to clarify the role played by the C-terminus 
in SmTGR catalyzed reactions. 
    
4.5.1 Enzymatic activities of U597C SmTGR 
The reducing activity of the enzyme has been tested towards various 
substrates, i.e.: (i) DTNB and Trx, to assess the functionality of the TR domain; (ii) 
the mixed disulphide formed by hydroxyethil-disulfide (HED) and GSH in the 
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presence of yeast GR, to evaluate the Grx activity of the enzyme; and (iii) the 
oxidized glutathione (GSSG) to measure the GR activity (see Chapter 3). 
 
 
 DTNB reduction Trx reduction Grx (+yeastGR) GR 
§SmTGRwt 114 6.37 1867 71.5 
SmTGRtr 710 N.D. 220 205 
U597C SmTGR 90 202 430 N.D. 
 
Table 6: Km (µM) for different enzymatic reactions 
§
 values taken from Kuntz et al. [29] 
 
 
 
DTNB 
reduction 
Trx 
reduction 
Grx 
(+yeastGR) GR 
§SmTGRwt 16 30 17.8 21.7 
SmTGRtr 1.2 N.D. 6.44 0.19 
U597C 
SmTGR 0.98 0.085 6.0 N.D. 
Table 7: kcat (s-1) for different enzymatic reactions 
§
 values taken from Kuntz et al. [29] 
 
 
 
Results and discussion 
 
84 
Relatively to DTNB reduction and Grx activity, the U597C SmTGR behaves 
like SmTGRtr, having similar steady state parameters (Tab. 6-7). However 
differently from the Sec-containing enzyme, in both mutants the Grx activity is 
detectable only if external GR is added (data not shown). Taken together these 
results prove that the U597C mutant has both functional FAD active site and Grx 
domain, but the U597C mutation prevents the internal transfer of reducing 
equivalents from the C-terminus to the Grx domain. Moreover U597C SmTGR is 
able to reduce SmTrx in the insulin assay (see Chapter 3), contrary to the truncated 
form, even if the enzyme turnover is low if compared with the wild-type enzyme 
(Tab. 7). This datum indicates that the C-terminus of the crystallized U597C mutant 
is functional, but confirms the hypothesized role of Sec in improving the catalytic 
efficiency of the enzyme [117]. Finally U597C SmTGR does not present a 
detectable activity (up to 4 µM enzyme) in reducing GSSG (GR activity), as 
opposite to the wt enzyme [29] and to the truncated enzyme [75] (Tab. 6-7). 
Although at the moment it is not possible to formulate an obvious explanation to this 
observation, some hypothesis may be advanced. On the one hand the fact that the 
Cys mutant does not retain any GR activity, with respect to the truncated form of the 
enzyme, could be explained recalling the hypothesis that the entire C-terminal arm 
of the enzyme may hinder the entrance of GSSG in its reducing site giving their 
structural resemblance [117]. On the other hand the behaviour of the U597C mutant 
in comparison with the wt enzyme suggests that Sec has a central role in the 
reduction of GSSG onto the Grx domain. In this respect the substitution Sec to Cys 
(Sec pKa= 5.2; Cys pKa= 8.5; [126]) determines a different net charge on the C-
terminal arm, which might hinder its movement towards the Grx domain. In 
conclusion, the following hypotheses may be proposed: (i) the GR activity of the 
wild type SmTGR is mainly due to the reduction of GSSG by the Grx domain, 
which in turn is internally reduced by electron transfer from the FADH2, via the 
C154-C159 couple and the C-terminal arm. (ii) The GR activity of the truncated 
SmTGR is GR-like, i.e. is due to the binding of GSSG in proximity of the C154-
C159 couple on the TR domain. (iii) In the mutant U597C the GR activity is 
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undetectable because the internal reduction of the Grx domain is inefficient, due to 
the mutation, and because the C596-C597 couple on the C terminal arm competes 
with GSSG for binding to the C154-C159 couple. 
 
4.5.2 Reductive and oxidative half reactions of U597C SmTGR 
The reduction of U597C SmTGR by NADPH and the further oxidation of the 
reduced enzyme by its physiological substrate SmTrx has been studied by mean of 
time resolved spectroscopy and the results are reported below. Both processes are 
referred to as “half-reactions” being representative of the electron entry into and exit 
from SmTGR respectively. 
The former reaction was followed in a stopped-flow experiment in which the 
concentrations of both the enzyme and NADPH were systematically varied, in order 
to determine the order of the reaction and the kinetic constants (see Chapter 3). 
Since the two reagents (NADPH and SmTGR) are required, the process is expected 
to be a second order bimolecular reaction. Fig. 32A shows the absorption spectra of 
U597 SmTGR, recorded as a function of time, after the addition of NADPH. The 
wavelengths of 460 and 560 nm have been selected for further analysis, being 
representative of the spectral changes of the FAD cofactor (the absorption at 460 is 
due to the oxidized flavin) and of the charge transfer complex formed between FAD 
and the C154-C159 couple (detected at 560 nm) [127]. The time course recorded at 
460 nm (Fig. 32B), corresponding to the experiment reported in panel A, is biphasic 
and may be fitted to a two step pseudo-first order sequential mechanism, using the 
integrated equation developed by Bateman [128]. The rate constants obtained are 
both second order, with values of 4x106 and 1x106 M-1s-1, for the first and second 
step of the reaction respectively (Fig. 32B). 
The time resolved spectra and the overall behavior of the reaction resembles 
those recorded  under similar experimental conditions for TR from Drosophila 
melanogaster (DmTR) [127]. The main difference between DmTR and SmTGR 
behavior may be detected in the spectral region around 680 nm, where in DmTR a 
change in absorbance during the reduction reaction is ascribed to the formation of a 
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transient charge-transfer complex between  FADH2 and NADP+. No spectral 
changes could be visualized around 680 nm for the schistosoma enzyme, probably 
indicating that the charge-transfer complex does not accumulate in the reaction. 
By means of absorbance spectroscopy, the re-oxidation of SmTGR (reduced 
by stoichiometric amounts of NADPH) by the physiological substrate SmTrx has 
been also followed. This reaction is accompanied by a decrease of absorbance at 550 
nm and an increase of the peak at 460 nm, as a result of the progressive oxidation of 
the flavin (Fig. 32C). The time course at 460 nm is shown in Fig. 32D, and is well 
described by a second order rate constant of 0.8x104 M-1s-1. This value is 
approximately two orders of magnitude lower than that reported by Kuntz et al. for 
the wild type enzyme [29], consistent with the important role played by Sec in the 
reduction of the physiological substrate. 
In conclusion both the reduction and oxidation half cycles of SmTGR are rate 
limited by second order kinetic processes, and accumulation of a Michaelis type 
complex does not occur at the concentration used. 
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Fig. 32: Reductive and oxidative half reactions of U597C SmTGR, spectrophotometric experiments. 
Panel A. Spectra of 3.5µM U597C SmTGR reduced with 5µM NADPH recorded in a stopped-flow 
apparatus. The decrease of the FAD peak at 460 nm and the increase of the absorbance around 550 nm 
due to the formation of the charge transfer complex are shown. Spectra were recorded every 5ms from 5 to 
500 ms and then every 50 ms up to 5500 ms. Panel B. Time course recorded at 460 nm relative to the 
experiment reported in Panel A fitted with a double exponential. The first process is assigned to the 
reduction of the FAD by NADPH (k = 4x106 M-1s-1) to form the two electrons reduced species EH2; the 
second one is the perturbation of the cofactor spectrum due to the formation of the EH4 species (k = 1x106 
M-1s-1). Panel C. Spectra of reduced U597C SmTGR (3.0µM) oxidized by SmTrx (7 µM) recorded in a 
spectrophotometer apparatus. The decrease of absorbance of the charge transfer complex around 550 nm 
and the increase of the FAD peak at 460 nm are shown. Panel D. Time course at 460 nm relative to the 
experiment reported in Panel C fitted to a single exponential. The second order process is assigned to the 
oxidation of the FADH2 of SmTGR by SmTrx (k = 0.8x104 M-1s-1). 
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4.6 Modeling of the complexes mediating the electron-transfer from SmTGR to 
both Grx domain and SmTrx 
Unfortunately, the observations coming from X-ray crystallography presented 
above lack details about the last steps of the catalytic cycle of SmTGR, i.e. the 
transfer of reducing equivalents from the C-terminus of the enzyme to either the Grx 
domain or the SmTrx. Hence two models are proposed below for both the 
interaction of the C-terminal arm with the Grx domain (Model 1) and the complex 
formed between SmTGR and SmTrx (Model 2). Structure 3 and Structure 4 of 
U597C SmTGR and the structure of oxidized SmTrx (PDB code: 2XBI) have been 
used in the modeling. A brief description of the 3D organization of SmTrx, which 
has not been presented in the preceding sections, is summarized below. 
SmTrx presents the typical thioredoxin fold, made up by a five-stranded β 
sheet (β1−5) capped on each side by two α helices (α1,3  and α2,4) [112] (Fig. 33). 
The conserved active site amino acids W33–C34–G35–P36–C37 link the strand β2 
to helix α2, and are arranged in a β−turn shape. The redox site formed by C34 and 
C37 is oxidized, the distance between the two sulphurs being 2.1 Å. This cysteine 
pair is shielded from the solvent by the C-terminal portion of helix α2 and by the 
loop between α3 and β4 and by the active site loop itself. As a result of this 
architecture, C34 works as the nucleophilic cysteine towards its substrates, being 
more exposed to the solvent, while C37 is buried and could act as the resolving 
cysteine [129]. Both the aspartate (D28) and the H-bonded water molecule 
(D28(OD1)-O = 2.7 Å) responsible for the deprotonation of the resolving cysteine 
(C37) during the redox cycle, are present (Fig. 33). 
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Fig. 33: Cartoon representation of the 3D structure of the oxidized form of SmTrx, showing the typical 
thioredoxin fold. Residues known to be relevant for the catalysis are represented in sticks. 
 
 
4.6.1 Model 1. The C-terminus of SmTGR onto the Grx domain 
The starting point for this model is represented by the superposition of the two 
C-terminal residues (C597 and G598), visible in Structure 4 of U597C SmTGR, to 
the analogue residues (Cys and Gly) of the GSH molecule bound onto the Grx 
domain in Structure 4 of the same enzyme (see Chapter 3). After the structural 
superposition, using K586 as pivot residue, a simple rotation on the psi angle of 
K586 of monomer B (in blue in Fig. 34A-34B) brings the C-terminal arm onto the 
redox site of the Grx domain of the adjacent monomer A (in red in Fig. 34A-34B).  
The model clarifies the functional role of the TGR dimer. Indeed, the 
dimerization is made necessary by the fact that the Grx domain of each monomer is 
much closer to the C-terminal arm of the opposite monomer (~ 20 Å) than to the C-
terminal arm of the same monomer (~ 65 Å); distances were measured between C28 
of both monomers and K586 of monomer B as found in Structure 3. 
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Fig 34: Model of the interaction between the C-terminus of SmTGR and the Grx domain. Panel A: 
Superposition between Structure 3 and Model 1. A rotation on the pivot residue K586/A (visualized 
as a full black circle) brings the C-terminus of monomer B from the position found in Structure 3 (in 
cyan) to the Grx domain of monomer A (from Model 1, in blue). The superposition between the last 
two residues of the C-terminus (C597-G598 in blue sticks) and the analogue residues of GSH (in 
cyan sticks, as bound in Structure 4) is also shown. The distances between Cα of K586 and Cα of 
C597 and between the former and the Cα of the GSH Cys are shown. Panel B: Zoom of the 
superposition between C597-G598 (blue sticks) of the C-terminal arm and the GSH (cyan sticks) 
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onto the Grx redox site (green sticks). Panel C: Model 2. The relative location of SmTrx and 
SmTGR in the modelled complex is shown (SmTrx in grey; subunit A in red and subunit B of 
SmTGR in blue; Grx domains in green. Panel D: The SmTrx binding site on SmTGR in Model 2. 
The magnification allows to visualize the redox sites of both enzymes. The main side chains 
involved in the contact between SmTrx and SmTGR are shown in sticks.  
 
4.6.2 Model 2. The complex between SmTGR and SmTrx 
With the aim to find a docking surface for the external substrate SmTrx, a 
surface complementarity search between the two proteins was carried out, followed 
by automated cycles of restrained refinement in order to minimize the energy and 
regularize the geometry, avoiding possible clashes (see Chapter 3). SmTrx can be 
docked onto U597C SmTGR in a surface cleft at the bottom of the TR domain, 
opposite to the Grx domain (Fig. 34C-34D). This cleft, formed by residues 
belonging to the C-terminus of monomer B and to the FAD binding site of subunit 
A, has a complementary surface to the stretch from W33 to K38 of SmTrx, which 
contains the active site couple C34-C37. In particular, W33 of SmTrx fits into a 
hydrophobic pocket formed by residues of monomer A of SmTGR (V155, I160, 
L164, L208); K38 of SmTrx is engaged in a salt bridge with D517 of the subunit B 
of SmTGR; and C34 (the most external of the active site Cys couple) ends up at 2.0 
Å distance from C597 of SmTGR subunit B (Fig. 34C-34D). The geometry of this 
mixed disulfide bond is superimposable to the mixed S-S bond found in the 
crystallographic complex of E. coli TR-Trx (PDB code: 1F6M, [130]), supporting 
the plausibility of this model. Another independent support to the model comes from 
the structures of Trx from other species, which show that the Trp adjacent to the 
catalytic site is engaged in hydrophobic contacts upon dimerization [129]. 
 
4.7 The catalytic mechanism of SmTGR 
By combining the structural and functional data presented above (see sections 
4.4-4.6) an hypothesis of the catalytic mechanism of SmTGR may be formulated 
(Fig. 22). It may be assumed that the mechanism below described for the Sec-Cys 
mutant of the worm enzyme is plausible and consistent with the Sec-containing 
wild-type enzyme, as a consequence of the following observations: (i) the only 
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structure of a Sec-containing rat TR shows the stereochemistry of the C-terminal 
arm to be very similar to that seen in Structure 3 [131]; and (ii) the functional 
characterization of U597C SmTGR indicates that the enzyme has fully functional 
FAD and Grx redox sites and an active C-terminal arm (see section 4.5.1). 
For the sake of clarity the enzymatic process has been divided into two half-
processes, comprising the transfer of reducing equivalents inside the TR domain of 
SmTGR (from NADPH to the C-terminus) and the exchange of electrons between 
the reduced C-terminal arm and its substrates outside the TR domain, represented by 
either the Grx domain or the external SmTrx. 
 
4.7.1 Electron flow within the TR domain: from NADPH to the C-terminus 
The  catalytic cycle starts with the transfer of two electrons from NADPH to 
the primary redox center (constituted by FAD and the couple C154-C159) of the 
oxidized enzyme (Structure 1, Eox). The product of this reaction is the EH2A species, 
where the FAD cofactor has been reduced to FADH2 (Fig. 22). The kinetic 
experiments (see section 4.5.2) proved that this step is rate limited by the formation 
of the complex FADH2-NADP+ and hence second order. 
Since the primary redox center of the enzyme has the ability to accept four 
electrons, rather than two, a charge transfer state is populated as the product, in 
which electrons move back and forth between the flavin and the Cys couple (EH2B). 
This mixed valency state exchanges electrons with the C-terminal redox center, 
comprising residues C596-C597 (EH2C). 
Those enzyme molecules in which the primary redox centre is fully oxidized 
because of this internal electron transfer are thus able to accept two more electrons 
coming from a new molecule of NADPH (EH4A). This is the second reaction step 
and implies little further reduction of the FAD, since it mainly occurs on those 
enzyme molecules in which the cofactor has been reoxidized. In those molecules in 
which the C-terminal redox center has been already reduced, the second couple of 
electrons may be exchanged between the FAD and the C154-C159 couple (EH4B), 
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leading to a partial re-oxidation of the FAD cofactor, which can be seen in the time 
absorbtion spectra at 460 nm at longer times (Fig. 32B). 
Structure 2 and Structure 4, which have been obtained in the presence of 
excess reductants (NADPH and GSH), probably are representative of the species 
called EH4, having two electrons stored on the FAD/C154-C159 redox center and 
two additional electrons localized on the C-terminal C597-C598 couple. However 
the two structures are also compatible with the EH2 reduced form, bearing the 
reducing equivalents on the FAD/C154-C159 site, because of the fact that the C-
terminal segment is not visible in the 3D structure and it is a reasonable assumption 
that the overall structure of SmTGR is not affected by the redox state of the 
disordered C-terminal residues. Finally Structure 3, which clearly shows one 
ordered C-terminus per dimer, carrying the C596-C597 couple fully reduced, may be 
assigned either to the EH4 reduced form or to the minor fraction of EH2 species in 
which the electrons have been internally transferred from the FAD/C154-C159 to 
the C-terminal redox center (EH2C), in view of the fact that the resolution of the 
structure does not allow the detection of the redox state of the C154-C159 couple. In 
agreement with Bauer and co-workers [127], Structure 3 is supposed to be ready to 
transfer reducing equivalents to its substrates, such as Trx  and/or the Grx domain. 
 
4.7.2 Electrons exit from the TR domain: from the C-terminus to either SmTrx 
or the Grx domain 
Once the reductive half-reaction is finished with the formation of the EH4B 
species, the oxidative half-reaction may start. A mixed disulphide is formed between 
the C-terminal sulphur groups of SmTGR and the catalytic C34-C37 couple of 
SmTrx. The reduced SmTrx is released and SmTGR is recycled back to the EH2B 
form (Fig. 22). Looking at Structure 3, the C-terminal arm is solvent exposed and 
~13 Å apart from the isoalloxazine ring, in a position suitable to supply reducing 
equivalents to SmTrx (Fig. 30). The C-terminal arm is probably quite mobile in 
solution and one can assume that only a further slight movement is sufficient to 
shuttle electrons from C154-C159 to Trx. Electrostatic interactions between the C-
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terminal arm of one subunit and a positive surface on the symmetric subunit 
(contributed by K124, K128 and R450, see Fig. 30) may suggest a mechanism 
whereby the motion of the former depends on its oxidation state. It may be 
hypothesized that the C-terminus contacts the external surface of enzyme when 
reduced, while it slides back into the FAD binding site upon oxidation (the net 
charge of the C-terminus dropping from -2 to -1, Sec being completely ionized at 
physiological pH). 
The C-terminal arm of SmTGR is also involved in the reduction of the Grx 
domain and thus in the Grx activity of the enzyme, as demonstrated by experiments 
on TGR from different organisms [48, 78, 132]. Structural motions compatible with 
internal electron transfer are required in order to bring the mobile C-terminus onto 
the Grx redox site and Structure 4 and Model 1 give some hints on this movement. 
Indeed in Structure 4 the GSH molecule is bound to the active site of the Grx 
domain, with its sulphurs group 3.1 Å far from C28 of the protein (Fig. 31). 
Moreover, as shown in Model 1, by means of a rotation of the C-terminus of 
Structure 4 around the Cα-C bond of K586, the C597-G598 pair of subunit B 
superimposes to GSH bound to the Grx domain of subunit A (Fig. 34A-34B). This 
motion is made possible by the fact that, from K586 onwards, the C-terminus  is 
unstructured and anchored by only a few contacts with the rest of the protein (as 
seen in Structure 3). Two more structural features need to be pointed out: (i) the last 
two residues of SmTGR, i.e. Sec-Gly, resemble the Cys-Gly moiety of GSH (except 
for the selenium atom, Fig. 34A-34B); and that (ii) the distance between Cα of 
K586/B and C597/B (~ 23 Å) is comparable with that between Cα of K586/B and 
the sulphurs group of GSH bound onto the Grx domain of monomer A (~ 26 Å, Fig. 
34A). Based on these observations, a rigid body rotation on the pivot residue K586 
is sufficient to bring the C-terminus of monomer B onto the GSH binding site on the 
Grx domain of monomer A (Fig. 34A-34B). Hence, it can be hypothesized that the 
C-terminal arm, once reduced, mimics free GSH by acting as a reducing agent on 
the Grx domain of the adjacent subunit of SmTGR. 
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5. CONCLUDING REMARKS 
 
The research project developed within this thesis is focused on the 
characterization of two proteins from the parasite Schistosoma mansoni, one of the 
three major species of the blood fluke Schistosoma infecting humans. The two 
enzymes here presented, i.e.: glutathione peroxidase (SmGpx) and thioredoxin 
glutathione reductase (SmTGR), have been chosen among the enzymatic 
components of the worm “detoxification pathway” (Fig. 7 pages 18-19). This system 
plays a key role in the protection of the worm from reactive oxygen species, thus 
guarantying its life-maintenance inside the human host. Indeed, on the one hand, 
SmGpx action is aimed to preserve the membrane lipids from oxidation, being the 
enzyme associated to the membranes and localized mainly in the worm tegument, at 
the host-parasite interface [69]. On the other hand TGR is the hub enzyme of the 
parasite detoxification pathway, hence it controls the whole transfer of reducing 
equivalents from NADPH either to the thioredoxin or glutathione systems, through 
intermediate enzymatic (Trx, Gpx, Tpx, Prx) and not-enzymatic partners 
(GSH/GSSG) [39]. A better understanding of the structure and mechanism of action 
of each component of this metabolic pathway may give new hints towards the 
finding of valid alternatives to the current treatment of the Schistosoma infection, 
which lacks an effective vaccine and is based on a main single drug since the mid-
1970s [23]. 
The first crystal structure at 1.0 and 1.7 Å resolution of two recombinant 
SmGpxs, carrying the active site mutations U43C and U43S respectively, has been 
presented in this work (Fig. 17A page 52). The Schistosoma enzyme, belonging to 
the monomeric class 4 (phospholipid hydroperoxide) Gpx, has been compared with 
the structurally characterized Sec-Cys mutant of the human homologue (HsGpx4) 
[63] and a peculiar reactivity of SmGpx has been detected. Indeed the structural 
superposition between SmGpx and HsGpx4 reveals that the two enzymes have a 
very similar 3D organization (RMSDoverall=0.68 Å), with the exception of the redox 
state of the catalytic cysteine, which is irreversibly oxidized to sulphonic acid (SO3-) 
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in SmGpx, while fully reduced and active in the human enzyme (Fig. 17B page 52). 
The geometry of the active site is conserved in SmGpx with respect to HsGpx4 and 
within the Gpx family, being the residues Q78, W132, and N133 placed at H-bond 
distance from Ocs43, but the over-oxidation of the cys residue fully compromised its 
catalytic activity against the substrates tested. This is quite expected if we consider 
that the catalytic cycle of selenium-containing Gpxs requires the enzyme to shuttle 
between two redox states; i.e.: an oxidized form (R-SeOH) and a reduced form (R-
Se-). Once reduced after the binding of the glutathione (GSH), Gpx is able to act on 
inorganic peroxides and lipid hydroperoxides, transforming them to hydroxides and 
recycling itself to the oxidized species, ready to start the cycle again (Fig. 9 page 
22). The over-oxidation of C43 of SmGpx to sulphonic acid is irreversible and thus 
prevents the enzyme even to enter the cycle. It has been recently suggested that 
selenocysteine (Sec) has a lower tendency to oxidation if compared with Cys, hence 
selenoenzymes (such as TR) are less prone to oxidation and consequent inactivation, 
even under conditions of oxidative stress [133, 134]. This could be the case of 
SmGpx: the Sec-containing wild-type enzyme should not undergo the spontaneous 
over-oxidation observed for the recombinant Cys mutant, thus preserving the 
glutathione peroxidase activity of the parasite inside the human host. 
The greater tendency to auto-oxidation of C43 in SmGpx with respect to C46 
of HsGpx4 may be justified by slight differences between the catalytic sites of the 
two enzymes. Indeed, in the SmGpx, the surface pocket hosting the catalytic cys 
presents on the one hand an increased accessibility to the solvent if compared with 
the human enzyme (being area and volume of the pocket 140Å2/ 94Å3 for U43C 
SmGpx and 93Å2/ 72Å3 for HsGpx4 respectively), and on the other hand it has a 
greater polarity, which might promote the entrance of water molecules and metal 
ions favoring the oxidation of C43 to sulphonic acid (Fig. 18A-18B page 56). 
The pocket hosting C43 in SmGpx may be divided in two half-clefts, namely 
“active-site cleft” and “secondary cleft”, and C43 seems to act as a flexible barrier in 
between (Fig. 18C page 56). The two half-clefts were identified through both a static 
(CASTp algorithm) and dynamic (MD simulations) analysis, and the latter proved 
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that their volume distribution is subjected to dynamic fluctuations during the 
catalytic cycle of the enzyme, probably allowing these clefts to host specific 
substrates such as GSH and phospholipid hydroperoxides. It is difficult to establish 
which one of the two half-clefts is mainly involved in the binding of either one or 
the other substrate, because of the lack of a structure of SmGpx in its ligated form. 
However, some observations need to be pointed out: (i) the secondary cleft may be 
easily superimposed to the GSH binding site already suggested for bovine Gpx [62], 
(ii) the high concentration of positive charges in the secondary cleft is compatible 
with the binding of glutathione; and (ii) both half-clefts may contribute to the 
binding of the phospholipids hydroperoxides, whose negatively-charged head may 
be placed in a positive region of the secondary cleft (hosting a sulphate anion in the 
crystallographic structure), and the hydrophobic tails layered over an extended 
hydrophobic surface on the top of the active site cleft (Fig. 18D page 56). 
In conclusion, by combining static crystallography with molecular dynamics 
simulations, a hypothesis for the substrate binding sites on SmGpx has been 
proposed. Moreover it is known that the particular tissue distribution of SmGpx at 
the host-parasite interface has made it a candidate of choice for the design of a 
vaccine against schistosomiasis, like other schistosome antioxidant enzymes 
(SmSOD and SmGST) [20, 69]. In this respect the availability of an atomic 
resolution structure of this enzyme, though in an inactive state, may represent a 
useful first step toward the localization of its epitopes. 
While SmGpx seems more suitable as a vaccine candidate, SmTGR, the 
second enzyme here described, has been demonstrated to be a target of choice for 
old and new antischistosomal drugs [29]. In fact, with respect to its mammalian 
counterparts (TR, thioredoxin reductase, and GR, glutathione reductase), the worm 
TGR exhibits a peculiar 3D organization and mechanism of action, both investigated 
in this work. More in detail the catalytic cycle of SmTGR has been mapped through 
the structural characterization of the Sec597Cys mutant in different redox states, i.e.: 
the oxidized form (at 1.9 Å resolution); the NADPH- and GSH-bound forms (2.3 Å 
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and 1.9 Å, respectively); and the partially reduced enzyme (3.1 Å), showing the 
physiological dimer and the entire C-terminus of one subunit. 
SmTGR is a homodimeric flavoprotein. As it appears from the 
crystallographic structures here presented, the enzyme results from the fusion of a 
larger TR domain with a smaller Grx domain, and presents one molecule of FAD 
non-covalently bound to each TR domain (Fig. 23A and 25, pages 69 and 70 
respectively). This unusual architecture reflects the peculiar reactivity of the parasite 
SmTGR, which is able to exploit three different catalytic activities, i.e.: thioredoxin 
reductase, glutathione reductase, and glutaredoxin activity, thus fully replacing TR, 
GR and Grx of the human host. 
The whole redox activity of the wild type SmTGR derives from the contribute 
of three main active centers: (i) the FAD redox site with the near-by C154-C159 
couple, (ii) the C-terminal U596-C597 redox couple, and (iii) the Grx redox site 
hosting the C28-C31 active residues (Fig. 23A page 69). The C-terminal segment of 
each monomer is an unstructured region, which may undergo motions in order to 
reach and transfer electrons to the FAD active site of the adjacent monomer, thus 
making the enzyme a functional dimer. The Structure 3 here presented, showing the 
C-terminal cys couple of one monomer located at 13Å distance from the C154-C159 
couple of the adjacent monomer, supports this statement (Fig. 30 page 81). 
In order to enter the catalytic cycle the oxidized SmTGR accepts reducing 
equivalents by NADPH. The NADPH molecule binds on the re-face of the FAD 
cofactor and is sandwiched between the isoalloxazine ring of FAD and the aromatic 
ring of Y296. As also observed for human TR and GR, Y296, which points towards 
the flavin in the oxidized form of the enzyme (Eox, Structure 1, Fig. 28 page 74), 
swings upon NADPH binding in a stacked position with the nicotinamide ring of 
NADPH and the isoalloxazine ring of FAD (Structure 2, Fig. 29 page 78). Electrons 
flow from NADPH to the cofactor, and then to the C154-C159 active couple. The C-
terminus carrying the residues C596-C597 is able to pick up electrons from the 
C154-C159 redox site, leading to the formation of the partially reduced form of the 
enzyme observed in Structure 3 (Fig. 30 page 81). Once the first couple of electrons 
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has reached the C-terminus, the FAD active site is ready to accept a second couple 
of electrons from NADPH, thus generating the four electrons reduced form of 
SmTGR. Two kinetic constants have been assigned to both the first reduction step, 
which forms the two electrons reduced species EH2 (k = 4x106 M-1s-1); and to the 
second reduction step, which leads to the formation of the EH4 species (k = 1x106 
M-1s-1). 
Once fully reduced, the C-terminal arm should transfer reducing equivalents 
either to the Grx domain of the enzyme, or to the external substrate SmTrx. In this 
respect is important to point out that the C-terminal segment of SmTGR appears 
from Structure 3 to be solvent exposed and quite mobile, above all in view of the 
fact that from K586 onwards it is unstructured and anchored by only a few contacts 
with the rest of the protein. SmTrx can be placed in a surface cleft of SmTGR, 
formed by residues belonging to the C-terminus of one monomer and to the FAD 
binding site of the adjacent monomer, at the bottom of the TR domain in Structure 
3, and a mixed disulphide may be formed between the active site C34 of SmTrx and 
the C597 of SmTGR, located at 2.0 Å distance from each other (Fig. 34C-34D page 
90). The geometry of the resulting disulphide bond is superimposable to the mixed 
S-S bond already found in the crystallographic complex of E. coli TR-Trx, thus 
proving the plausibility of the model [130]. Moreover, looking at Structure 4, which 
shows a GSH binding site on the Grx domain of SmTGR and taking into account 
that the C-terminal tetrapeptide (G-C-U-C) may mimic the GSH moiety, a model for 
the contact between the C-terminus and the Grx redox site may be built after a 
motion around the pivot residue K586 (Fig. 34A-34B page 90). Hence the 
mechanism here proposed assume that the C-terminus may deliver electrons 
selectively to different acceptors shuttling between two alternative positions: (i) it 
may be located in close proximity to the FAD redox site of the adjacent monomer 
(as observed in Structure 3) where it can both pick up electrons from the C154-C159 
couple and transfer them to the oxidized SmTrx, as has been observed in TR 
enzymes, or (ii) it may internally transfer reducing equivalents to the Grx domain by 
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occupying the region which is involved in the binding of GSH (as observed in 
Structure 4).  
In conclusion the structural analysis of SmTGR here presented, combined with 
the suggested models, gives some hints toward the understanding of the mechanism 
of action of the enzyme. The complex structural organization is aimed to make the 
parasite enzyme able to fulfill a complex function, i.e.: linking the two principal 
antioxidant detoxification pathways (GSH and Trx pathways), which are distinct in 
the human host. A recent paper [47] reports the presence of TGR only in parasitic 
flatworms but not in the free-living species of the same phylum, where separated GR 
and TR exist similarly to mammals. Hence SmTGR should guarantee selective 
advantages to the parasites. The internal reduction of the Grx domain in TGR 
enzymes could be vital for parasites, which spend all their life in the host organism 
under constant oxidative attack [78]. Under these conditions, sudden fluctuations of 
the GSH concentration may impair Grx activity and increase the percentage of 
protein glutathionylation, thus compromising some vital activities of the parasite 
[46, 135]. The peculiar intramolecular electron pathway of TGR, which carries 
reducing equivalents from NADPH to the internal Grx domain through the C-
terminus, may assure deglutathionylation of target proteins independently of GSH, 
hence helping the parasites to survive into the human body by circumventing the 
host-induced oxidative stress. 
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